<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAN</journal-id>
<journal-id journal-id-type="hwp">sptan</journal-id>
<journal-title>Therapeutic Advances in Neurological Disorders</journal-title>
<issn pub-type="ppub">1756-2856</issn>
<issn pub-type="epub">1756-2864</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1756285611422267</article-id>
<article-id pub-id-type="publisher-id">10.1177_1756285611422267</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Moussouttas</surname><given-names>Michael</given-names></name>
</contrib>
</contrib-group>
<author-notes id="author-notes1-1756285611422267">
<corresp id="corresp1-1756285611422267">Michael Moussouttas, MD Assistant Professor of Neurology, Cerebrovascular and Neurocritical Care Division, Thomas Jefferson Medical Center, 900 Walnut Street, Suite 200, Philadelphia, PA 19107, USA, <email>arista1@pol.net</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>5</volume>
<issue>1</issue>
<fpage>43</fpage>
<lpage>56</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Intracerebral hemorrhage (ICH) represents 10–15% of all cerebrovascular events, and is associated with substantial morbidity and mortality. In contrast to ischemic cerebrovascular disease in which acute therapies have proven beneficial, ICH remains a more elusive condition to treat, and no surgical procedure has proven to be beneficial. Aspects pertinent to medical ICH management include cessation or minimization of hematoma enlargement, prevention of intraventricular extension, and treatment of edema and mass effect. Therapies focusing on these aspects include prothrombotic (hemostatic) agents, antihypertensive strategies, and antiedema therapies. Therapies directed towards the reversal of antithrombosis caused by antiplatelet and anticoagulant agents are frequently based on limited data, allowing for diverse opinions and practice styles. Several newer anticoagulants that act by direct thrombin or factor Xa inhibition have no natural antidote, and are being increasingly used for various prophylactic and therapeutic indications. As such, these new anticoagulants will inevitably pose major challenges in the treatment of patients with ICH. Ongoing issues in the management of patients with ICH include the need for effective treatments that not only limit hematoma expansion but also result in improved clinical outcomes, the identification of patients at greatest risk for continued hemorrhage who may most benefit from treatment, and the initiation of therapies during the hyperacute period of most active hemorrhage. Defining hematoma volume increases at various anatomical locations that translate into clinically meaningful outcomes will also aid in directing future trials for this disease. The focus of this review is to underline and discuss the various controversies and challenges involved in the medical management of patients with primary and antithrombotic-related ICH.</p>
</abstract>
<kwd-group>
<kwd>antithrombotic</kwd>
<kwd>challenges</kwd>
<kwd>controversies</kwd>
<kwd>hematoma expansion</kwd>
<kwd>intracerebral hemorrhage</kwd>
<kwd>medical management</kwd>
<kwd>primary</kwd>
<kwd>review</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1756285611422267" sec-type="intro">
<title>Introduction</title>
<p>Intracerebral hemorrhage (ICH) represents 10–15% of all cerebrovascular events [<xref ref-type="bibr" rid="bibr97-1756285611422267">Sudlow and Warlow, 1997</xref>] and is associated with a 30-day mortality rate of approximately 40%, with an additional 40% of patients remaining disabled at 6 months [<xref ref-type="bibr" rid="bibr20-1756285611422267">Counsell <italic>et al</italic>. 1995</xref>] Various medical strategies have been proposed and studied in the treatment of primary ICH from hypertensive or amyloid arteriopathies, including prothrombotic agents to create hemostasis in ruptured vessels, antihypertensive/normotensive treatments to limit perfusion pressures into damaged vessels, and antiedema medications to decrease perihematomal edema and mass effect.</p>
<p>The management of antithrombotic-associated ICH may allow for more goal-directed interventions (correction of abnormal laboratory values), but is frequently based on limited and inadequate evidence. The recent introduction of a newer generation of anticoagulants with novel mechanisms of action will inevitably provide even greater challenges to the management of patients with ICH. This article reviews the contemporary literature about the medical treatment of primary and antithrombotic-associated ICH, and explores current existing controversies and anticipated future challenges in the treatment of ICH.</p>
</sec>
<sec id="section2-1756285611422267">
<title>Primary intracerebral hemorrhage</title>
<p>In patients with primary ICH, clinical and radiological determinants of outcome include patient age, clinical status upon presentation, ICH location and size, and intraventricular hemorrhage (IVH) [<xref ref-type="bibr" rid="bibr38-1756285611422267">Hemphill <italic>et al</italic>. 2001</xref>]. Among these variables, only ICH size and IVH are amenable to intervention, given that intracerebral expansion and intraventricular extension may occur as a result of the dynamic nature of the hematoma [<xref ref-type="bibr" rid="bibr94-1756285611422267">Steiner <italic>et al</italic>. 2006a</xref>; <xref ref-type="bibr" rid="bibr15-1756285611422267">Brott <italic>et al</italic>. 1997</xref>]. Being that IVH represents a consequence of hemorrhage enlargement and hematoma size [<xref ref-type="bibr" rid="bibr68-1756285611422267">Moussouttas <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr36-1756285611422267">Hallevi <italic>et al</italic>. 2008</xref>], the single most addressable target in ICH management becomes the limitation of hematoma expansion during the acute phase when continued active hemorrhage is most likely to occur [<xref ref-type="bibr" rid="bibr23-1756285611422267">Davis <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr15-1756285611422267">Brott <italic>et al</italic>. 1997</xref>]. Additional possible complications of any ICH include satellite hemorrhages, hydrocephalus, edema and mass effect (<xref ref-type="fig" rid="fig1-1756285611422267">Figure 1</xref>).</p>
<fig id="fig1-1756285611422267" position="float">
<label>Figure 1.</label>
<caption><p>Hypertensive lenticular hemorrhage in a patient taking aspirin, imaged just under 4 h from onset and reimaged 24 h after onset. Computerized tomography scans show marked enlargement of hematoma, with satellite hemorrhages, surrounding edema, substantial mass effect, intraventricular extension, and hydrocephalus caused by trapping of the left lateral ventricle.</p></caption>
<graphic xlink:href="10.1177_1756285611422267-fig1.tif"/>
</fig>
<sec id="section3-1756285611422267">
<title>Predictors of hematoma expansion</title>
<p>In an effort to identify patients at greatest risk for hematoma expansion, and therefore those that may most benefit from acute therapeutic interventions, various clinical, laboratory and radiological factors have been investigated and identified. Determinants of hematoma expansion have included anticoagulant (warfarin) use [<xref ref-type="bibr" rid="bibr30-1756285611422267">Flibotte <italic>et al</italic>. 2004</xref>], larger initial size [<xref ref-type="bibr" rid="bibr14-1756285611422267">Broderick <italic>et al</italic>. 2007b</xref>], irregular shape and density [<xref ref-type="bibr" rid="bibr7-1756285611422267">Barras <italic>et al</italic>. 2009</xref>], and serological evidence of systemic inflammation [<xref ref-type="bibr" rid="bibr91-1756285611422267">Silva <italic>et al</italic>. 2005</xref>]. Contrast extravasation into the hematoma body, indicative of persisting vascular mural permeability and ongoing hemorrhage, has been identified as an independent predictor of hematoma enlargement and adverse outcomes [<xref ref-type="bibr" rid="bibr1-1756285611422267">Almandoz <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr35-1756285611422267">Goldstein <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr107-1756285611422267">Wada <italic>et al</italic>. 2007</xref>].</p>
</sec>
<sec id="section4-1756285611422267">
<title>Prothrombotic strategies</title>
<p>Prothrombotic strategies have centered around the use of recombinant activated factor VII (rF-VIIa), a compound originally used in the treatment of hemophilia [<xref ref-type="bibr" rid="bibr82-1756285611422267">Roberts <italic>et al</italic>. 2004</xref>]. Upon injury to the endothelium, local release of thromboplastin and initial aggregation of platelets induce the conversion of VII to active VIIa, which converts factor X to Xa, thereby initiating the extrinsic coagulation cascade that results in thrombin generation and fibrin deposition [<xref ref-type="bibr" rid="bibr82-1756285611422267">Roberts <italic>et al</italic>. 2004</xref>]. In an attempt to augment local thrombosis at the site of vessel rupture, and thereby decrease hemorrhage and hematoma expansion, rF-VIIa was studied in two major trials of primary ICH.</p>
<p>The initial phase II study was a randomized trial of rF-VIIa (40, 80 and 160 µg) <italic>versus</italic> placebo in patients diagnosed using computerized tomography (CT) within 3 h of onset [<xref ref-type="bibr" rid="bibr61-1756285611422267">Mayer <italic>et al</italic>. 2005</xref>]. For the nearly 400 enrolled patients, mean treatment time was 167 min. The 80 µg and 160 µg doses resulted in decreased hematoma expansion (rF-VIIa 14% and 11% <italic>versus</italic> placebo 29%), and decreased rates of IVH and edema at 24 h. Decreases in 90-day mortality (18% <italic>versus</italic> 29%), and improved functional outcomes as measured by several grading scales were also observed in the active treatment arms. However, more systemic thrombotic events occurred with rF-VIIa (7% <italic>versus</italic> 2%), mostly in patients receiving the 160 µg dose.</p>
<p>The similar phase III FAST study tested rF-VIIa (20 and 80 µg) <italic>versus</italic> placebo, enrolled over 800 patients, and administered treatment within a mean time of 160 min [<xref ref-type="bibr" rid="bibr62-1756285611422267">Mayer <italic>et al</italic>. 2008</xref>]. Again a decrease in hematoma expansion was noted for the 80 µg group (11% <italic>versus</italic> 26%), yet this time no difference was noted in IVH rate, edema volume, mortality or disability (26% and 29% <italic>versus</italic> 24%). Possible reasons for the contrasting negative findings have included unexpected low mortality and disability in the placebo group (19% and 24%, respectively), more frequent IVH in patients receiving rF-VIIa (38% <italic>versus</italic> 29%), and more thrombotic (mostly coronary) complications in those receiving rF-VIIa (8% <italic>versus</italic> 4%).</p>
<p>A <italic>post-hoc</italic> analysis of the FAST trial identified a subgroup of patients in whom rF-VIIa 80 µg/kg may be beneficial [<xref ref-type="bibr" rid="bibr63-1756285611422267">Mayer <italic>et al</italic>. 2009</xref>]. Patients younger than 70 years, with an ICH volume less than 60 ml, an IVH volume less than 5 ml, and time to treatment up to 2.5 h were found to have a lower chance of a poor outcome (Rankin score 5–6) compared with placebo (odds ratio 0.28; 95% confidence interval 0.08–1.06). A greater mean reduction in hematoma volume was also noted in comparison to the entire study group (7.3 ml <italic>versus</italic> 3.8 ml; <italic>p</italic> = 0.02). These findings, however, are yet to be verified in a prospective trial.</p>
</sec>
<sec id="section5-1756285611422267">
<title>Antihypertensive strategy</title>
<p>Antihypertensive strategies have evolved on the premise that perfusion pressure inside the vessel lumen may promote continued hemorrhage from regions with compromised mural integrity and local loss of autoregulation [<xref ref-type="bibr" rid="bibr66-1756285611422267">Morgensetern <italic>et al</italic>. 2010</xref>]. However, the exact role of hypertension following acute ICH has never been definitively elucidated [<xref ref-type="bibr" rid="bibr46-1756285611422267">Jauch <italic>et al</italic>. 2006</xref>] and controversy exists as to whether elevated pressures contribute to hematoma expansion, result from the hematoma causing compression of central structures and intracranial pressure elevations, or simply represent a marker of severity and worse prognosis [<xref ref-type="bibr" rid="bibr66-1756285611422267">Morgensetern <italic>et al</italic>. 2010</xref>]. To date there have been two randomized trials assessing whether various ranges of systemic pressures reduce hematoma expansion and provide benefit in patients with acute ICH.</p>
<p>The INTERACT study enrolled over 400 patients presenting with systolic pressures of 150–180 mmHg, who were randomized within 6 h of onset to conservative (systolic &lt;140 mmHg) <italic>versus</italic> liberal (systolic &lt;180 mmHg) control [<xref ref-type="bibr" rid="bibr3-1756285611422267">Anderson <italic>et al</italic>. 2008</xref>]. Goal pressures were to be achieved within 1 h of starting intravenous nicardipine, and were maintained for 24 h. Mean initial systolic pressures were similar in the two groups, and overall mean time to treatment was 4.5 h from onset. At 24 h, less ICH expansion was seen in the conservative arm (14% <italic>versus</italic> 36%), as well as less substantial enlargement defined as volume increase greater than 33% (15% <italic>versus</italic> 33%), but no difference was observed in edema volume on day 3 or on the clinical outcome mortality/disability (48% <italic>versus</italic> 49%) at 90 days [<xref ref-type="bibr" rid="bibr2-1756285611422267">Anderson <italic>et al</italic>. 2010</xref>]. The anticipated INTERACT II study will be an open-label but assessor-blinded trial that will randomize 2800 patients presenting with systolic pressures of 150–220 mmHg to two treatment arms (systolic &lt;140 <italic>versus</italic> &lt;180 mmHg) within 6 h of ICH onset for a period of 7 days. The primary outcome will be 90-day mortality/dependency, while secondary outcomes will assess treatment within 4 h, levels of disability and quality of life.</p>
<p>The ATACH study randomized 80 patients with systolic pressures greater than 170 mmHg to one of three target systolic pressures (110–140, 140–170, 170–200 mmHg) within 6 h of onset using intravenous nicardipine for 24 h [<xref ref-type="bibr" rid="bibr5-1756285611422267">ATACH Investigators, 2010</xref>]. Preliminary results demonstrated greater rates of treatment failure, adverse events, neurologic worsening, and mortality in the most aggressively treated group. Three-month outcomes comparing dichotomized groups above and below the medians for two treatment parameters (systolic reduction at 6 h and systolic reduction area under the curve) revealed trends towards improved radiographical and clinical outcomes, but no definite advantage to aggressive treatment [<xref ref-type="bibr" rid="bibr79-1756285611422267">Qureshi <italic>et al</italic>. 2010</xref>].</p>
<p>Various theories have been proposed to explain the failure of antihypertensive therapy to improve clinical outcomes despite mitigating hematoma expansion. Low baseline clinical severity, small initial hematoma volumes, relatively minor decreases in hematoma enlargement from active treatment, lack of impact on perihematomal edema, possible neurological deterioration from induced ischemia in vulnerable regions, inadequate study power, and hypertension as a consequence and not cause of ICH expansion have all been postulated [<xref ref-type="bibr" rid="bibr2-1756285611422267">Anderson <italic>et al</italic>. 2010</xref>, <xref ref-type="bibr" rid="bibr3-1756285611422267">2008</xref>; <xref ref-type="bibr" rid="bibr5-1756285611422267">ATACH Investigators, 2010</xref>; <xref ref-type="bibr" rid="bibr79-1756285611422267">Qureshi <italic>et al</italic>. 2010</xref>].</p>
</sec>
<sec id="section6-1756285611422267">
<title>Perihematomal edema and inflammation</title>
<p>Studies on the treatment of perihematomal edema and inflammation have used hyperosmolar and steroidal agents in an attempt to minimize or reduce regional mass effect and tissue injury. The variety of agents used speaks to the uncertainty that exists regarding the exact nature of the edema – extruded serum from hematoma coagulation and contraction, vasogenic edema from local disruption of capillary membranes, or cytotoxic cellular injury [<xref ref-type="bibr" rid="bibr40-1756285611422267">Hoff and Xi, 2003</xref>]. Controversy also exists as to whether the diffusion restricted areas of edema on magnetic resonance imaging (MRI) represent cytotoxic edema secondary to compromised microvascular perfusion (in which case, antihypertensive therapy may be detrimental) or cytotoxic edema due to structural and biochemical damage from the hemorrhage.</p>
<p>Perfusion studies that demonstrated hypoperfusion to the perihematomal area were interpreted as representing penumbra with potential for ischemia [<xref ref-type="bibr" rid="bibr90-1756285611422267">Siddique <italic>et al</italic>. 2002</xref>]. However, histological investigations revealed mitochondrial dysfunction without ischemia [<xref ref-type="bibr" rid="bibr49-1756285611422267">Kim <italic>et al</italic>. 2006</xref>], implying that the reduced perfusion and metabolism may indicate tissue hibernation [<xref ref-type="bibr" rid="bibr78-1756285611422267">Qureshi <italic>et al</italic>. 2009</xref>]. MRI studies have characterized the perihematomal edema as predominantly extracellular [<xref ref-type="bibr" rid="bibr16-1756285611422267">Carhuapoma <italic>et al</italic>. 2000</xref>], with lesser areas of cytotoxic edema unrelated to the degree of hypoperfusion and thus unlikely ischemic [<xref ref-type="bibr" rid="bibr73-1756285611422267">Olivot <italic>et al</italic>. 2010</xref>]. Whether edema volume actually impacts clinical outcome remains to be determined [<xref ref-type="bibr" rid="bibr4-1756285611422267">Arima <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr32-1756285611422267">Gebel <italic>et al</italic>. 2002</xref>], thus possibly negating the need for future trials of antiedema agents in patients without substantial mass effect or intracranial hypertension.</p>
<p>Only two studies have tested the utility of dexamethasone in patients with ICH. The first was limited by very small patient numbers, partial open-label treatment allocation, unavailability of modern imaging techniques, inclusion of patients with hemorrhagic infarction, and the use of nonstandardized clinical grading scales [<xref ref-type="bibr" rid="bibr99-1756285611422267">Tellez and Bauer, 1973</xref>]. The second enrolled larger numbers, randomized patients in a blinded fashion, included only patients with supratentorial ICH diagnosed by CT, and stratified patients according to Glasgow Coma Scale score [<xref ref-type="bibr" rid="bibr77-1756285611422267">Poungvarin <italic>et al</italic>. 1987</xref>]. No differences in mortality were noted, while greater rates of infection and hyperglycemia occurred with dexamethsone. The study was terminated prematurely.</p>
<p>In the first study of hyperosmolar therapy, 216 patients with primary supratentorial ICH were randomized within 24 h of onset to intravenous glycerol <italic>versus</italic> saline for 6 consecutive days. No difference in 180-day outcome was seen, yet anemia due to hemolysis occurred with glycerol [<xref ref-type="bibr" rid="bibr110-1756285611422267">Yu <italic>et al</italic>. 1992</xref>]. Mannitol (20% 100 ml) was tested in a randomized, controlled trial of 128 patients presenting within 6 days of a primary supratentorial CT confirmed ICH [<xref ref-type="bibr" rid="bibr65-1756285611422267">Misra <italic>et al</italic>. 2005</xref>]. Thirty-day mortality and 90-day functionality did not differ between the two groups. Physiological studies have failed to demonstrate an advantage to treatment with mannitol in terms of augmenting regional perfusion following ICH [<xref ref-type="bibr" rid="bibr48-1756285611422267">Kalita <italic>et al</italic>. 2004</xref>].</p>
<p>Data from animal models and human subjects suggest that hypothermia 35°C may reduce perihematomal edema, and thus possibly concurrent neurotoxicity, via enhancement of endothelial integrity, anti-inflammatory actions and neuroprotective properties [<xref ref-type="bibr" rid="bibr51-1756285611422267">Kollmar <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr58-1756285611422267">MacLellan <italic>et al</italic>. 2006</xref>]. Potential adverse developments, however, may include rebound edema and intracranial pressure increase [<xref ref-type="bibr" rid="bibr89-1756285611422267">Schwab <italic>et al</italic>. 2001</xref>], and various multisystem complications [<xref ref-type="bibr" rid="bibr76-1756285611422267">Polderman and Herold, 2009</xref>]. Whereas hypothermia may also theoretically attenuate any evolving perihematomal ischemia [<xref ref-type="bibr" rid="bibr50-1756285611422267">Kollmar <italic>et al</italic>. 2002</xref>], the hypertension that typically accompanies hypothermia may risk ICH enlargement [<xref ref-type="bibr" rid="bibr59-1756285611422267">MacLellan <italic>et al</italic>. 2004</xref>]. No randomized controlled trials have been performed.</p>
</sec>
<sec id="section7-1756285611422267">
<title>Summary and future strategies</title>
<p>In conclusion, contemporary studies have demonstrated the ability of prothrombotic and antihypertensive modalities to reduce ICH enlargement, but not to alter clinical outcome [<xref ref-type="bibr" rid="bibr79-1756285611422267">Qureshi <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr3-1756285611422267">Anderson <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr62-1756285611422267">Mayer <italic>et al</italic>. 2008</xref>, <xref ref-type="bibr" rid="bibr61-1756285611422267">2005</xref>]. This paradox may be explained by the magnitude of hematoma volume difference achieved between the treatment and placebo arms. In all studies performed, absolute volume differences between treatment groups were typically on the order of 2–5 ml, which when compared with mean hematoma volumes of 20–30 ml represents a very small fraction of the entire hemorrhagic mass.</p>
<p>Recent articles have attempted to define an absolute or relative volume increase which may reliably determine clinical worsening among patients with ICH, and which may be suitable for study as an endpoint in randomized trials [<xref ref-type="bibr" rid="bibr25-1756285611422267">Dowlatshahi <italic>et al</italic>. 2011</xref>]. Absolute volume increases of 12 ml or more, and not relative increases, were found to have the best predictive value for clinical deterioration [<xref ref-type="bibr" rid="bibr25-1756285611422267">Dowlatshahi <italic>et al</italic>. 2011</xref>]. The authors correctly concluded that many patients with ICH may not benefit from acute therapies because of the rarity of cases in which hematoma expansion exceeds 12 ml. They propose that future studies may require very large numbers of patients to demonstrate any treatment effect, or may need to selectively include only those patients at greatest risk for substantial expansion [<xref ref-type="bibr" rid="bibr25-1756285611422267">Dowlatshahi <italic>et al</italic>. 2011</xref>].</p>
<p>Omitted from this informative review was the role that hemorrhage location and intraventricular extension play in determining clinical worsening. Posterior fossa lesions of even 3 cm diameter may cause substantial functional compromise and clinical deterioration by local compression of adjacent structures or by obstructive hydrocephalus [<xref ref-type="bibr" rid="bibr66-1756285611422267">Morgensetern <italic>et al</italic>. 2010</xref>]. In addition, hemorrhages in deep paraventricular areas (thalamus and caudate head) are typically smaller and undergo less expansion than those of the lenticular nuclei or lobar locations, yet result in similar outcomes [<xref ref-type="bibr" rid="bibr68-1756285611422267">Moussouttas <italic>et al</italic>. 2011</xref>]. As such, ICH location must be considered a crucial factor in defining the ‘critical’ amount of hematoma volume that determines clinical worsening. To date, no clinical studies have addressed this issue.</p>
<p>Therefore, whereas cerebral ischemia represents an acute process for which successful treatment may be instituted during the first few hours following onset, ICH may represent a ‘hyperacute’ process that may necessitate treatment within the first 1 or 2 h of onset. The small increases in hematoma volumes observed in major clinical trials of patients diagnosed within 3–6 h [<xref ref-type="bibr" rid="bibr79-1756285611422267">Qureshi <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr3-1756285611422267">Anderson <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr62-1756285611422267">Mayer <italic>et al</italic>. 2008</xref>, <xref ref-type="bibr" rid="bibr61-1756285611422267">2005</xref>] and the frequent evidence of IVH upon initial scanning [<xref ref-type="bibr" rid="bibr94-1756285611422267">Steiner <italic>et al</italic>. 2006a</xref>] support the concept of greatest hematoma expansion within a very narrow and early time frame.</p>
</sec>
</sec>
<sec id="section8-1756285611422267">
<title>Antithrombotic-related intracerebral hemorrhage</title>
<p>Risk factors for antithrombotic ICH have mostly been studied in the context of warfarin use, and include age, hypertension, leukoaraiosis, amyloid angiopathy, and intensity of anticoagulation [<xref ref-type="bibr" rid="bibr13-1756285611422267">Broderick <italic>et al</italic>. 2007a</xref>]. Evidence-based guidelines regarding the use of reversing agents and hematologous transfusions for the management of ICH due to antithrombotic drugs are limited by incomplete and inadequate data, which has allowed for various therapeutic options and for diverse treatment preferences.</p>
<sec id="section9-1756285611422267">
<title>Hematoma characteristics</title>
<p>In contrast to primary ICH, antithrombotic hemorrhages (and, in particular, warfarin-related ICHs) demonstrate larger initial volumes and greater hematoma enlargement, likely due to more pronounced and prolonged extravasation [<xref ref-type="bibr" rid="bibr22-1756285611422267">Cucchiara <italic>et al</italic>. 2008</xref>]. Antithrombotic ICHs are also more irregular in contour such that visual estimation of volume may be most accurately approximated by the equation ABC/3 (instead of ABC/2, which is typically used for nonantithrombotic hematomas) [<xref ref-type="bibr" rid="bibr43-1756285611422267">Huttner <italic>et al</italic>. 2006b</xref>], where ABC represents the product of each of the longest three-dimensional diameters [<xref ref-type="bibr" rid="bibr52-1756285611422267">Kothari <italic>et al</italic>. 1996</xref>]. Finally, hemorrhages related to antithrombotics frequently exhibit distinct fluid levels [<xref ref-type="bibr" rid="bibr33-1756285611422267">Gebel <italic>et al</italic>. 1998</xref>], indicating separation of plasma and cellular components because of impaired thrombus formation [<xref ref-type="bibr" rid="bibr44-1756285611422267">Ichikawa and Yanagihara, 1998</xref>], and may be multicompartmental [<xref ref-type="bibr" rid="bibr33-1756285611422267">Gebel <italic>et al</italic>. 1998</xref>]. Theoretically, less edema may develop as a result of impairment in the thrombin generation, which typically increases vascular permeability [<xref ref-type="bibr" rid="bibr86-1756285611422267">Sansing <italic>et al</italic>. 2003</xref>], but this has not consistently been observed [<xref ref-type="bibr" rid="bibr95-1756285611422267">Steiner <italic>et al</italic>. 2006b</xref>].</p>
</sec>
<sec id="section10-1756285611422267">
<title>Antiplatelet agents</title>
<p>Controversy exists over whether ICH in the setting of antiplatelet use warrants platelet transfusion because the literature is conflicting as to whether antiplatelet agents even contribute to hematoma expansion or to adverse outcomes. Evidence that antiplatelet agents increase hematoma expansion and worsen outcome [<xref ref-type="bibr" rid="bibr109-1756285611422267">Yildiz <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr21-1756285611422267">Creutzfeldt <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr101-1756285611422267">Toyoda <italic>et al</italic>. 2009</xref>, <xref ref-type="bibr" rid="bibr100-1756285611422267">2005</xref>; <xref ref-type="bibr" rid="bibr53-1756285611422267">Lacut <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr93-1756285611422267">Sorimachi <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr85-1756285611422267">Saloheimo <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr83-1756285611422267">Roquer <italic>et al</italic>. 2005</xref>] is countered by studies that report no increase in hematoma volume or worsened outcome [<xref ref-type="bibr" rid="bibr67-1756285611422267">Moussouttas <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr87-1756285611422267">Sansing <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr45-1756285611422267">Ishibashi <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr14-1756285611422267">Broderick <italic>et al</italic>. 2007b</xref>; <xref ref-type="bibr" rid="bibr31-1756285611422267">Foerch <italic>et al</italic>. 2006</xref>], and by animal studies showing no differences in volumes or outcomes [<xref ref-type="bibr" rid="bibr54-1756285611422267">Lauer <italic>et al</italic>. 2011</xref>].</p>
<p>These contrasting data may be attributed to differences in study methodology (for example, inclusion or exclusion of posterior fossa hemorrhages which may be predisposed to intraventricular extension yet undergo limited enlargement from anatomic restrictions, visual versus computerized hematoma volume measurement techniques, and outcome measures of &gt;33% <italic>versus</italic> any measurable volume increase). However, the discrepancies may also be due to unreliability of reported antiplatelet use, the variety of agents used at different doses, and interindividual differences in antiaggregant activity and resistance [<xref ref-type="bibr" rid="bibr69-1756285611422267">Naidech <italic>et al</italic>. 2009a</xref>]. To date, retrospective studies have failed to show benefit from platelet transfusion in patients with ICH on antiplatelet agents [<xref ref-type="bibr" rid="bibr26-1756285611422267">Ducret <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr21-1756285611422267">Creutzfeldt <italic>et al</italic>. 2009</xref>].</p>
<p>Presently, only small observational studies have assessed the impact of platelet inhibition, as measured by aggregometry assays, upon ICH enlargement and clinical outcome. One study identified greater hematoma expansion in patients with impaired platelet activity, as well as worse outcomes at 90 days compared with those with normal platelet action [<xref ref-type="bibr" rid="bibr71-1756285611422267">Naidech <italic>et al</italic>. 2009c</xref>]. A second study associated reduced platelet activity with the occurrence of IVH, greater ICH score, and greater risk for mortality [<xref ref-type="bibr" rid="bibr70-1756285611422267">Naidech <italic>et al</italic>. 2009b</xref>]. The investigators of these studies also identified greater platelet inhibition among patients taking combination antiplatelet regimens compared with those on single agents only [<xref ref-type="bibr" rid="bibr69-1756285611422267">Naidech <italic>et al</italic>. 2009a</xref>].</p>
<p>Unfortunately, unlike measures of anticoagulant activity [for example, international normalized ratio (INR) for warfarin or partial thromboplastin time (PTT) for heparin], no consistently reliable or globally validated method exists for quantifying the antiaggregant activity induced by antiplatelet agents [<xref ref-type="bibr" rid="bibr11-1756285611422267">Breet <italic>et al</italic>. 2010</xref>], and therefore no means exists by which to select those patients who may be most at risk for continued hemorrhage, or those who may most benefit from transfusion therapy. Currently, the use of platelet transfusions in patients with ICH is unproven and is considered investigational [<xref ref-type="bibr" rid="bibr66-1756285611422267">Morgensetern <italic>et al</italic>. 2010</xref>]. Potential complications of transfusion that must be considered include volume overload, transfusion reactions, anaphylaxis, acute lung injury, and infection [<xref ref-type="bibr" rid="bibr81-1756285611422267">Refaai <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section11-1756285611422267">
<title>Heparin and warfarin</title>
<p>In reversing heparin anticoagulation, protamine remains the single most effective and only needed treatment, which can rapidly and completely normalize PTT following administration [<xref ref-type="bibr" rid="bibr39-1756285611422267">Hirsh and Raschke, 2004</xref>]. Conversely, several treatment options exist for the management of warfarin-related ICH with elevated INR, including cobalamin, fresh frozen plasma (FFP), prothrombin complex concentrates (PCCs) and rF-VIIa. In the absence of randomized, controlled studies, diverse and varied opinions exist regarding the most appropriate therapy or combination of therapies [<xref ref-type="bibr" rid="bibr95-1756285611422267">Steiner <italic>et al</italic>. 2006b</xref>]. In contrast to antiplatelet agents, warfarin use has been convincingly connected to hematoma expansion and adverse outcome [<xref ref-type="bibr" rid="bibr22-1756285611422267">Cucchiara <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr30-1756285611422267">Flibotte <italic>et al</italic>. 2004</xref>].</p>
<p>Cobalamin counteracts warfarin inhibition of synthetic enzymes, and provides hemostatic protection beyond the limited lifespan of administered factors [<xref ref-type="bibr" rid="bibr95-1756285611422267">Steiner <italic>et al</italic>. 2006b</xref>]. Intravenous cobalamin reverses coagulopathy faster than oral dosing [<xref ref-type="bibr" rid="bibr108-1756285611422267">Watson <italic>et al</italic>. 2001</xref>], and subcutaneous administration is discouraged due to unpredictable absorption [<xref ref-type="bibr" rid="bibr80-1756285611422267">Raj <italic>et al</italic>. 1999</xref>]. A dose of 10 mg is generally recommended [<xref ref-type="bibr" rid="bibr66-1756285611422267">Morgensetern <italic>et al</italic>. 2010</xref>], and risk of anaphylaxis from intravenous administration is considered to be low [<xref ref-type="bibr" rid="bibr29-1756285611422267">Fiore <italic>et al</italic>. 2001</xref>]. Since reversal takes several hours [<xref ref-type="bibr" rid="bibr108-1756285611422267">Watson <italic>et al</italic>. 2001</xref>], concurrent administration of coagulation factors is essential. In one study, normalization of INR by 2 h occurred in 84% of patients given PCC, in 39% of those given FFP and in 0% of those given cobalamin [<xref ref-type="bibr" rid="bibr42-1756285611422267">Huttner <italic>et al</italic>. 2006a</xref>]. Hematoma expansion occurred in 19%, 33% and 50% respectively.</p>
<p>Among coagulation factor replenishing agents, PCCs and rF-VIIa are capable of normalizing INR within minutes, whereas FFP may require hours [<xref ref-type="bibr" rid="bibr66-1756285611422267">Morgensetern <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr95-1756285611422267">Steiner <italic>et al</italic>. 2006b</xref>]. This may be because of the variable concentrations of coagulation factors provided by FFP, and therefore to variable completeness of factor repletion [<xref ref-type="bibr" rid="bibr13-1756285611422267">Broderick <italic>et al</italic>. 2007a</xref>]. Treatment delays may also be encountered in the time needed for preparation and infusion of FFP [<xref ref-type="bibr" rid="bibr9-1756285611422267">Bershad and Suarez, 2010</xref>]. Failure to achieve hemostasis following INR correction with FFP has also been observed [<xref ref-type="bibr" rid="bibr55-1756285611422267">Lee <italic>et al</italic>. 2006</xref>], possibly due to persistently low factor IX levels [<xref ref-type="bibr" rid="bibr60-1756285611422267">Makris <italic>et al</italic>. 1997</xref>]. FFP may also be associated with diminishing gains, whereby large amounts of FFP result in negligible INR changes when the INR is ≤1.5 [<xref ref-type="bibr" rid="bibr41-1756285611422267">Holland and Brooks, 2006</xref>]. Because FFP administration can be complicated by volume overload and heart failure, transfusion reactions and anaphylaxis, and the potential for infectious transmission, some authorities have suggested alternative agents [<xref ref-type="bibr" rid="bibr95-1756285611422267">Steiner <italic>et al</italic>. 2006b</xref>].</p>
<p>As a recombinant preparation composed of one coagulation protein, rF-VIIa lacks many of the factors inhibited by warfarin, and thus may not completely reverse warfarin anticoagulation. Studies on human subjects have demonstrated an inability for rF-VIIa to reverse warfarin-induced hemorrhagic diathesis despite normal INR [<xref ref-type="bibr" rid="bibr92-1756285611422267">Skolnick <italic>et al</italic>. 2010</xref>], and experimental studies have confirmed the ability of rF-VIIa to correct the INR yet fail to restore thrombin generation [<xref ref-type="bibr" rid="bibr98-1756285611422267">Tanaka <italic>et al</italic>. 2008</xref>]. The transient duration of activity and possible need for repeated dosing, in conjunction with the known systemic thrombotic complications, may also pose a substantive risk when using rF-VIIa [<xref ref-type="bibr" rid="bibr13-1756285611422267">Broderick <italic>et al</italic>. 2007a</xref>]. As a result of these limitations, neurovascular societal guidelines have discouraged the use of this drug [<xref ref-type="bibr" rid="bibr66-1756285611422267">Morgensetern <italic>et al</italic>. 2010</xref>].</p>
<p>PCCs are an admixture of various coagulation factors, the exact composition and concentration of which varies depending on the specific formulation. However, all contain those factors inhibited by warfarin (II, VII, IX and X), and some provide a more ‘physiologically balanced’ preparation that includes inhibited anticoagulants (proteins C and S) [<xref ref-type="bibr" rid="bibr9-1756285611422267">Bershad and Suarez, 2010</xref>]. Like rF-VIIa, PCCs may provide for rapid correction of INR [<xref ref-type="bibr" rid="bibr24-1756285611422267">Dickneite, 2007</xref>] yet may also provide more complete reversal of coagulopathy [<xref ref-type="bibr" rid="bibr24-1756285611422267">Dickneite, 2007</xref>] and less risk for thromboembolic and ischemic complications [<xref ref-type="bibr" rid="bibr66-1756285611422267">Morgensetern <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr56-1756285611422267">Leissinger <italic>et al</italic>. 2008</xref>]. PCC use may also avoid many of the complications associated with FFP [<xref ref-type="bibr" rid="bibr9-1756285611422267">Bershad and Suarez, 2010</xref>]. As a result, leading neurovascular organizations have increasingly recommended PCCs for reversal of warfarin anticoagulation [<xref ref-type="bibr" rid="bibr66-1756285611422267">Morgensetern <italic>et al</italic>. 2010</xref>].</p>
</sec>
<sec id="section12-1756285611422267">
<title>Newer anticoagulants</title>
<p>The newer generation anticoagulants which act by direct thrombin inhibition or by direct Xa inhibition are administered by intravenous or oral route, and are variably indicated in the treatment of thrombotic conditions (venous thromboembolization and heparin-induced thrombocytopenia) and in preventing atrial fibrillation embolization [<xref ref-type="bibr" rid="bibr57-1756285611422267">Levy <italic>et al</italic>. 2010</xref>]. These agents will be increasingly seen in the setting of ICH because of the increasing use of oral medications which, unlike warfarin, do not require routine serological monitoring, and as a result of an aging population are more predisposed towards atrial fibrillation and cerebral amyloid angiopathy [<xref ref-type="bibr" rid="bibr105-1756285611422267">Vernooij <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr34-1756285611422267">Go <italic>et al</italic>. 2001</xref>]. The major challenge with these new agents will be reversal of anticoagulation in the setting of ICH, since no natural antidote or reversing medication exists for these compounds [<xref ref-type="bibr" rid="bibr57-1756285611422267">Levy <italic>et al</italic>. 2010</xref>].</p>
<p>Among the direct thrombin inhibitors are argatroban and the hirudin family of anticoagulants which are indicated in the setting of heparin-induced thrombocytopenia [<xref ref-type="bibr" rid="bibr57-1756285611422267">Levy <italic>et al</italic>. 2010</xref>], and dabigatran which recently demonstrated superior effectiveness and improved safety over warfarin in the outpatient management of atrial fibrillation and deep vein thrombosis/pulmonary embolism [<xref ref-type="bibr" rid="bibr19-1756285611422267">Connolly <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr88-1756285611422267">Schulman <italic>et al</italic>. 2009</xref>]. Of the direct factor Xa inhibitors, apixaban has shown greater efficacy over aspirin, and rivaroxaban a better safety profile than warfarin in patients with atrial fibrillation at risk for cardioembolization [<xref ref-type="bibr" rid="bibr17-1756285611422267">Cleland <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr18-1756285611422267">Connolly <italic>et al</italic>. 2011</xref>]. Low molecular weight heparin agents, heparinoids and fondoparinux, by inhibiting Xa via antithrombin, have been in use as substitutes for heparin in deep vein thrombosis prophylaxis, or for the treatment of venous thromboembolic disease [<xref ref-type="bibr" rid="bibr57-1756285611422267">Levy <italic>et al</italic>. 2010</xref>].</p>
<p>Currently, no medication or transfusion is capable of completely neutralizing the anticoagulant activity of the direct thrombin or (direct or indirect) factor Xa inhibitors, potentially rendering patients with ICH at great risk for continued hemorrhage, hematoma expansion, intraventricular extension, and added morbidity and mortality. In addition to possibly administering oral charcoal to any patient recently ingesting oral anticoagulants [<xref ref-type="bibr" rid="bibr47-1756285611422267">Johnson &amp; Johnson, New Brunswick, NJ; 2009</xref>; <xref ref-type="bibr" rid="bibr102-1756285611422267">Van Ryn <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr12-1756285611422267">Bristol Myers Squibb, New York, NY; 2007</xref>], empiric transfusion of plasma coagulation products or recombinant coagulation factors may be considered [<xref ref-type="bibr" rid="bibr103-1756285611422267">Van Ryn <italic>et al</italic>. 2010</xref>]. Given the more reliable composition of PCCs, and greater concentration of thrombin and factor X, PCCs may be preferred over FFP or rF-VIIa.</p>
<p>Importantly, the pharmacokinetic properties for some of these agents may allow a certain degree of hemostasis and partial control of hemorrhage to be achieved. Specifically, the degree of protein binding for any given agent may determine the extent to which removal by means of hemodialysis may be feasible and possibly advantageous. Since heparinoids [<xref ref-type="bibr" rid="bibr75-1756285611422267">Pfizer, New York, NY; 2007</xref>] hirudin-like agents [<xref ref-type="bibr" rid="bibr8-1756285611422267">Berlex, Montville, NJ; 2004</xref>] and dabigatran [<xref ref-type="bibr" rid="bibr10-1756285611422267">Boehringer Ingelheim, Ingelheim, Germany; 2010</xref>] possess relatively low or no protein binding, as opposed to other direct or indirect thrombin and factor Xa inhibitors, hemorrhage in conjunction with these agents may theoretically be more likely to respond to serologic extraction by dialysis [<xref ref-type="bibr" rid="bibr103-1756285611422267">Van Ryn <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr96-1756285611422267">Stratmann <italic>et al</italic>. 2004</xref>]. Unfortunately, the time required to place central access and administer hemodialysis may prove to be a costly limitation.</p>
<p>Monitoring the anticoagulant activity and effectiveness of reversal for the newer (and older) anticoagulants may be accomplished by measuring anti factor Xa activity for the direct and indirect Xa inhibitors, and by measuring PTT for the direct thrombin inhibitors. Dabigatran may also be monitored using the thrombin time assay, which provides the most linear measure of activity [<xref ref-type="bibr" rid="bibr10-1756285611422267">Boehringer Ingelheim, 2010</xref>], and rivaroxaban may be monitored by prothrombin time level but not INR, which is calibrated only for warfarin [<xref ref-type="bibr" rid="bibr47-1756285611422267">Johnson &amp; Johnson, 2009</xref>]. <xref ref-type="table" rid="table1-1756285611422267">Table 1</xref> provides a list of the laboratory tests that may be used to quantify anticoagulation, and the reversal agents for each antithrombotic drug.</p>
<table-wrap id="table1-1756285611422267" position="float">
<label>Table 1.</label>
<caption><p>List of half-life, laboratory tests, and reversal agents for various antithrombotic drugs.</p></caption>
<graphic alternate-form-of="table1-1756285611422267" xlink:href="10.1177_1756285611422267-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Antithrombotic</th>
<th align="left">T½</th>
<th align="left">Lab test</th>
<th align="left">Reversal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiplatelets</td>
<td>ASA 2–4 h/24–48 h</td>
<td>None universallyaccepted or validated</td>
<td>Platelet transfusion(investigational)</td>
</tr>
<tr>
<td/>
<td>Clopidogrel 8 h/4–7 days</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td>Dipyridamole 10 h/2–4 days</td>
<td/>
<td/>
</tr>
<tr>
<td>Warfarin</td>
<td>36–48 h</td>
<td>PT/INR</td>
<td>Vitamin K, PCC, FFP, rF-VIIa</td>
</tr>
<tr>
<td>Heparin</td>
<td>30–120 min (depending on dose)</td>
<td>PTT</td>
<td>Protamine</td>
</tr>
<tr>
<td>LMWH</td>
<td>3–6 h</td>
<td>Anti-Xa activity</td>
<td>Protamine (partially)</td>
</tr>
<tr>
<td>Danaparoid</td>
<td>18–28 h</td>
<td>Anti-Xa activity</td>
<td>None</td>
</tr>
<tr>
<td>Fondoparinux</td>
<td>18–22 h</td>
<td>Anti-Xa activity</td>
<td>None</td>
</tr>
<tr>
<td>Hirudin</td>
<td>60 min</td>
<td>PTT</td>
<td>None</td>
</tr>
<tr>
<td>Argatroban</td>
<td>45 min</td>
<td>PTT</td>
<td>None</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>12–16 h</td>
<td>PTT/TT</td>
<td>None</td>
</tr>
<tr>
<td>Apixaban</td>
<td>8–12 h</td>
<td>Anti-Xa activity</td>
<td>None</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>8–12 h</td>
<td>PT/anti-Xa activity</td>
<td>None</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1756285611422267">
<p>ASA, aspirin; FFP, fresh frozen plasma; INR, international normalized ratio; LMWH, low molecular weight heparins; PCC, prothrombin complex concentrates; PT, prothrombin time; PTT, partial thromboplastin time; rF-VIIa, recombinant activated factor VII; T½, half life; TT, thrombin time.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section13-1756285611422267" sec-type="conclusions">
<title>Conclusions and future research</title>
<p>Substantial deficiencies persist in evidence-based directives on the management of patients with antithrombotic related ICH. For antiplatelet agents, a standardized and validated method for measuring platelet inhibition from agents with different modes of action is desperately needed, not only for assessing treatment efficacy in preventing vascular thrombotic events [<xref ref-type="bibr" rid="bibr11-1756285611422267">Breet <italic>et al</italic>. 2010</xref>], but also for definitively determining whether the degree of antiaggregant activity correlates to ICH expansion [<xref ref-type="bibr" rid="bibr69-1756285611422267">Naidech <italic>et al</italic>. 2009a</xref>]. If such a correlation is determined, then randomized trials comparing platelet transfusion to supportive therapy will be needed to conclusively delineate the advantages and/or detriments incurred by transfusion.</p>
<p>Despite theoretical advantages and disadvantages among the various hemotogenous and reconstituted coagulation factor formulations available, sufficient clinical equipoise exists to justify a randomized trial comparing each of the major products, preferably in combination with cobalamin, so as to minimize excessive repeated administrations. Clinical, radiological (hematoma enlargement), and laboratory (INR) outcome measures will be imperative to determine the effectiveness of these therapies, and the reliability of commonly available serological coagulation tests. Documentation of adverse outcomes such as volume overload, immune reactions, infectious complications, and thrombotic events will be equally important.</p>
<p>For the new direct thrombin or factor X inhibitors, research to produce reversing agents is urgently needed given the increasing use of these anticoagulants and the inevitable cerebral and systemic hemorrhages that will ensue. Accurate reporting and comprehensive analysis of postmarketing data for these products is eagerly awaited, and must be compared against available information for the alternative and more traditional therapies, warfarin and aspirin. Subsequent studies to determine the impact of these antidotes in the setting of ICH will then be needed.</p>
<p>For any study of any antithrombotic-reversing modality, optimum quantification of dynamic hematoma evolution must be achieved, possibly by including only supratentorial ICH (or by dividing hemorrhages according to location), by employing computerized methods for comparing initial and subsequent hematoma volumes, and by analyzing final hematoma volume as a continuous and nominal variable (for example, volume increase &gt;33%). Obtaining information regarding impact upon perihematomal edema or in inducing cerebral ischemia will also be of interest.</p>
</sec>
<sec id="section14-1756285611422267">
<title>Reintroducing antithrombotics afterintracerebral hemorrhage</title>
<p>In patients with ischemic cerebrovascular disease, the decision on whether to reinstitute antithrombotic therapy following ICH entails careful consideration of the relative risks for thrombosis <italic>versus</italic> hemorrhage. Risk stratification must be based on the type and severity of ischemic disease, on the underlying cause of ICH, and on the added hemorrhage risk from antithrombosis. Annual risk for recurrent cerebral ischemic events depends on the mechanism involved and the number of coexisting comorbidities, and ranges from 7% to 15% [<xref ref-type="bibr" rid="bibr84-1756285611422267">Sacco <italic>et al</italic>. 2006</xref>]. Conversely, the yearly risk of hypertensive ICH recurrence is approximately 2% [<xref ref-type="bibr" rid="bibr6-1756285611422267">Bailey <italic>et al</italic>. 2001</xref>] whereas that due to amyloid angiopathy ranges from 5% to 15%, depending on genetic predisposition [<xref ref-type="bibr" rid="bibr72-1756285611422267">O’Donnell <italic>et al</italic>. 2000</xref>]. While risk of ICH recurrence does not appear to be increased by aspirin [<xref ref-type="bibr" rid="bibr106-1756285611422267">Viswanathan <italic>et al</italic>. 2006</xref>], the risk may be tripled by warfarin [<xref ref-type="bibr" rid="bibr104-1756285611422267">Vermeer <italic>et al</italic>. 2002</xref>].</p>
<p>For atrial fibrillation patients with lobar ICH, the risk of recurrent hemorrhage with warfarin may exceed that of embolization [<xref ref-type="bibr" rid="bibr27-1756285611422267">Eckman <italic>et al</italic>. 2003</xref>], leading some authorities to recommend antiplatelet agents [<xref ref-type="bibr" rid="bibr66-1756285611422267">Morgensetern <italic>et al</italic>. 2010</xref>]. The presence and quantity of microhemorrhages as detected by gradient-echo MRI may indicate and quantify risk for recurrent ICH in such situations, and aid in risk assessment [<xref ref-type="bibr" rid="bibr28-1756285611422267">Fan <italic>et al</italic>. 2003</xref>]. The newer oral anticoagulants that carry a lower risk for primary ICH than warfarin (∼0.2% <italic>versus</italic> 1% per year) [<xref ref-type="bibr" rid="bibr37-1756285611422267">Hart <italic>et al</italic>. 1995</xref>] may impact the decision on whether to restart anticoagulation, but rates of recurrent hemorrhages from these agents have yet to be determined. The timing of antithrombotic reintroduction following ICH is also a topic of uncertainty, with guidelines generally suggesting an abstinence period of 1–2 weeks for antiplatelet agents and 3–4 weeks for oral anticoagulants [<xref ref-type="bibr" rid="bibr66-1756285611422267">Morgensetern <italic>et al</italic>. 2010</xref>].</p>
</sec>
<sec id="section15-1756285611422267">
<title>Surgical management</title>
<p>The largest randomized study to assess the role of hematoma evacuation, STICH, enrolled 1033 patients with supratentorial ICH of at least 2 cm to early surgery (median 30 h from onset) <italic>versus</italic> medical treatment alone [<xref ref-type="bibr" rid="bibr64-1756285611422267">Mendelow <italic>et al</italic>. 2005</xref>]. Patients were eligible if clinical equipoise existed regarding the best treatment strategy, crossover was permitted in the event of neurological deterioration, and method of evacuation was determined by the involved surgeon. In the medical and surgical groups, evacuation was ultimately performed in 94% and 26% of patients, by craniotomy in 85% and 75% of cases, and with 6% needing reevacuation in each group. The primary outcome was functional status at 180 days relative to an admission prognosis score based on age, clinical condition and hematoma size. No differences were observed in favorable outcome from the primary endpoint measure (24% <italic>versus</italic> 26%), or in mortality between the two groups (37% <italic>versus</italic> 36%).</p>
<p>Subgroup analysis from STICH indicated a possible advantage to surgery in patients not in a coma with lobar hemorrhages, and in those with hematomas up to 1 cm from the cortical surface [<xref ref-type="bibr" rid="bibr64-1756285611422267">Mendelow <italic>et al</italic>. 2005</xref>]. The ongoing STICH II trial will assess the role of early surgery (&lt;48 h) in patients with lobar ICH less than 1 cm from the cortex surface and no IVH. Limitations to STICH include lack of true randomization given inclusion by the clinical uncertainty principle, inter-institutional variability in determining clinical equipoise, the relatively late timing of surgery, and the large amount of crossover from the medical arm to the surgical group. In a smaller randomized trial of patients with subcortical/deep hemorrhages of at least 30 ml randomized to hematoma removal or medical treatment within 8 h of onset, surgery resulted in improved outcomes for patients not in a coma with hematomas less than 80 ml (33% <italic>versus</italic> 9%), with no difference in mortality [<xref ref-type="bibr" rid="bibr74-1756285611422267">Pantazis <italic>et al</italic>. 2006</xref>].</p>
<p>Recently, interest has developed in less invasive stereotactic endoscopic aspiration techniques (variably infusing fibrinolytics), which reduce the likelihood of cerebral injury from surgery. The ongoing MISTIE trial is a dose finding and safety study of intrahematomal tissue plasminogen activator (tPA) infusion in patients with supratentrial ICH greater than 25 ml and symptoms within 72 h. In a related study, CLEAR-IVH will randomize patients with ICH and IVH who present within 24 h with a supratentorial hematoma less than 30 ml to 1–3 mg of tPA or saline via ventriculostomy. Primary endpoints will include mortality and complication rate for MISTIE, and rate of ventricular hemorrhage resolution for CLEAR-IVH. Finally, despite the absence of trial-based evidence, surgical evacuation is generally recommended for posterior fossa (cerebellar) hematomas that are 3 cm in diameter and causing clinical deterioration, stem compression or obstructive hydrocephalus [<xref ref-type="bibr" rid="bibr66-1756285611422267">Morgensetern <italic>et al</italic>. 2010</xref>].</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<p>The author has no conflicts of interest to declare.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Almandoz</surname><given-names>D.</given-names></name>
<name><surname>Yoo</surname><given-names>A.</given-names></name>
<name><surname>Stone</surname><given-names>M.</given-names></name>
<name><surname>Schaefer</surname><given-names>P.</given-names></name>
<name><surname>Oleinik</surname><given-names>A.</given-names></name>
<name><surname>Brouwers</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>The spot sign score in primary intracerebral hemorrhage identifies patients at highest risk of in-hospital mortality and poor outcome among survivors</article-title>. <source>Stroke</source> <volume>41</volume>: <fpage>54</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr2-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>C.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Arima</surname><given-names>H.</given-names></name>
<name><surname>Heeley</surname><given-names>E.</given-names></name>
<name><surname>Skulina</surname><given-names>C.</given-names></name>
<name><surname>Parsons</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Effects of early intensive blood pressure lowering treatment on the growth of hematoma and peerihematomal edema in acute intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>41</volume>: <fpage>307</fpage>–<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr3-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>C.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Arima</surname><given-names>H.</given-names></name>
<name><surname>Neal</surname><given-names>B.</given-names></name>
<name><surname>Peng</surname><given-names>B.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Acute Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT)</article-title>. <source>Lancet Neurology</source> <volume>7</volume>: <fpage>391</fpage>–<lpage>399</lpage>.</citation>
</ref>
<ref id="bibr4-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arima</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Heeley</surname><given-names>E.</given-names></name>
<name><surname>Skulina</surname><given-names>C.</given-names></name>
<name><surname>Parsons</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2009</year>) <article-title>Significance of perihematomal edema in acute intracerebral hemorrhage – the INTERACT Trial</article-title>. <source>Neurology</source> <volume>73</volume>: <fpage>1963</fpage>–<lpage>1968</lpage>.</citation>
</ref>
<ref id="bibr5-1756285611422267">
<citation citation-type="journal">
<collab>ATACH Investigators</collab>. (<year>2010</year>) <article-title>Antihypertensive treatment of acute cerebral hemorrhage</article-title>. <source>Crit Care Med</source> <volume>38</volume>: <fpage>637</fpage>–<lpage>648</lpage>.</citation>
</ref>
<ref id="bibr6-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bailey</surname><given-names>R.</given-names></name>
<name><surname>Hart</surname><given-names>R.</given-names></name>
<name><surname>Benavente</surname><given-names>O.</given-names></name>
<name><surname>Pearce</surname><given-names>L.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage</article-title>. <source>Neurology</source> <volume>56</volume>: <fpage>773</fpage>–<lpage>777</lpage>.</citation>
</ref>
<ref id="bibr7-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barras</surname><given-names>C.</given-names></name>
<name><surname>Tress</surname><given-names>B.</given-names></name>
<name><surname>Christensen</surname><given-names>S.</given-names></name>
<name><surname>MacGregor</surname><given-names>L.</given-names></name>
<name><surname>Collins</surname><given-names>M.</given-names></name>
<name><surname>Desmond</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2009</year>) <article-title>Density and shape as CT predictors of intracerebral hemorrhage growth</article-title>. <source>Stroke</source> <volume>40</volume>: <fpage>1325</fpage>–<lpage>1331</lpage>.</citation>
</ref>
<ref id="bibr8-1756285611422267">
<citation citation-type="book">
<collab>Berlex</collab> (<year>2004</year>) <article-title>Lepirudin</article-title>. <publisher-loc>Montville, NJ</publisher-loc>; <publisher-name>USA</publisher-name>.</citation>
</ref>
<ref id="bibr9-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bershad</surname><given-names>E.</given-names></name>
<name><surname>Suarez</surname><given-names>J.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Prothrombin complex concentrates for oral anticoagulant therapy related intracranial hemorrhge – a review of the literature</article-title>. <source>Neurocrit Care</source> <volume>12</volume>: <fpage>403</fpage>–<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr10-1756285611422267">
<citation citation-type="book">
<collab>Boehringer Ingelheim</collab> (<year>2010</year>) <article-title>Dabigatran etexilate</article-title>. <publisher-name>Ingelheim</publisher-name>, <publisher-loc>Germany</publisher-loc>.</citation>
</ref>
<ref id="bibr11-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Breet</surname><given-names>N.</given-names></name>
<name><surname>VanWerkum</surname><given-names>J.</given-names></name>
<name><surname>Bouman</surname><given-names>H.</given-names></name>
<name><surname>Kelder</surname><given-names>J.</given-names></name>
<name><surname>Ruven</surname><given-names>H.</given-names></name>
<name><surname>Bal</surname><given-names>E.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation</article-title>. <source>JAMA</source> <volume>303</volume>: <fpage>754</fpage>–<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr12-1756285611422267">
<citation citation-type="book">
<collab>Bristol Myers Squibb</collab> (<year>2007</year>) <article-title>Apixaban</article-title>. <publisher-loc>New York, NY; USA</publisher-loc>.</citation>
</ref>
<ref id="bibr13-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Broderick</surname><given-names>J.</given-names></name>
<name><surname>Connolly</surname><given-names>S.</given-names></name>
<name><surname>Feldmann</surname><given-names>E.</given-names></name>
<name><surname>Hanley</surname><given-names>D.</given-names></name>
<name><surname>Kase</surname><given-names>C.</given-names></name>
<name><surname>Krieger</surname><given-names>D.</given-names></name>
<etal/>
</person-group> (<year>2007a</year>) <article-title>Guidelines for the management of spontaneous intracerebral hemorrhage in adults</article-title>. <source>Stroke</source> <volume>38</volume>: <fpage>e391</fpage>–<lpage>e413</lpage>.</citation>
</ref>
<ref id="bibr14-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Broderick</surname><given-names>J.</given-names></name>
<name><surname>Diringer</surname><given-names>M.</given-names></name>
<name><surname>Hill</surname><given-names>M.</given-names></name>
<name><surname>Brun</surname><given-names>N.</given-names></name>
<name><surname>Mayer</surname><given-names>S.</given-names></name>
<name><surname>Steiner</surname><given-names>T.</given-names></name>
<etal/>
</person-group> (<year>2007b</year>) <article-title>Determinants of Intracerebral hemorrhage growth – an exploratory analysis</article-title>. <source>Stroke</source> <volume>38</volume>: <fpage>1072</fpage>–<lpage>1075</lpage>.</citation>
</ref>
<ref id="bibr15-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brott</surname><given-names>T.</given-names></name>
<name><surname>Broderick</surname><given-names>J.</given-names></name>
<name><surname>Kothari</surname><given-names>R.</given-names></name>
<name><surname>Barsan</surname><given-names>W.</given-names></name>
<name><surname>Tomsick</surname><given-names>T.</given-names></name>
<name><surname>Sauerbeck</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>1997</year>) <article-title>Early hemorrhge growth in patients with intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>28</volume>: <fpage>1</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr16-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carhuapoma</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Beauchamp</surname><given-names>N.</given-names></name>
<name><surname>Keyl</surname><given-names>P.</given-names></name>
<name><surname>Hanley</surname><given-names>D.</given-names></name>
<name><surname>Barker</surname><given-names>P.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Diffusion-weighted MRI and proton MR spectroscopic imaging in the study of secondary neuronal injury after intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>31</volume>: <fpage>726</fpage>–<lpage>732</lpage>.</citation>
</ref>
<ref id="bibr17-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cleland</surname><given-names>J.</given-names></name>
<name><surname>Coletta</surname><given-names>A.</given-names></name>
<name><surname>Buga</surname><given-names>L.</given-names></name>
<name><surname>Antony</surname><given-names>R.</given-names></name>
<name><surname>Pellicori</surname><given-names>P.</given-names></name>
<name><surname>Freemantle</surname><given-names>N.</given-names></name>
<etal/>
</person-group> (<year>2011</year>) <article-title>Clinical trials update from the American Heart Association Meeting 2010</article-title>. <source>Eur J Heart Fail</source> <volume>13</volume>: <fpage>460</fpage>–<lpage>465</lpage>.</citation>
</ref>
<ref id="bibr18-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Connolly</surname><given-names>S.</given-names></name>
<name><surname>Eikelboom</surname><given-names>J.</given-names></name>
<name><surname>Joyner</surname><given-names>C.</given-names></name>
<name><surname>Diener</surname><given-names>H.</given-names></name>
<name><surname>Hart</surname><given-names>R.</given-names></name>
<name><surname>Golitsyn</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2011</year>) <article-title>Apixaban in patients with atrial fibrillarion</article-title>. <source>N Eng J Med</source> <volume>364</volume>: <fpage>806</fpage>–<lpage>817</lpage>.</citation>
</ref>
<ref id="bibr19-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Connolly</surname><given-names>S.</given-names></name>
<name><surname>Ezekowitz</surname><given-names>M.</given-names></name>
<name><surname>Yusuf</surname><given-names>S.</given-names></name>
<name><surname>Eikelboom</surname><given-names>J.</given-names></name>
<name><surname>Oldgren</surname><given-names>J.</given-names></name>
<name><surname>Parekh</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Dabigatran versus warfarin in patients with atrial fibrillation</article-title>. <source>N Eng J Med</source> <volume>361</volume>: <fpage>1139</fpage>–<lpage>1151</lpage>.</citation>
</ref>
<ref id="bibr20-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Counsell</surname><given-names>C.</given-names></name>
<name><surname>Boonyakarnukul</surname><given-names>S.</given-names></name>
<name><surname>Dennis</surname><given-names>M.</given-names></name>
<name><surname>Sandercock</surname><given-names>P.</given-names></name>
<name><surname>Bamford</surname><given-names>J.</given-names></name>
<name><surname>Burn</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>1995</year>) <article-title>Primary intracerebral hemorrhage in the Oxfordshire Community Stroke Project</article-title>. <source>Cerebrovasc Dis</source> <volume>5</volume>: <fpage>26</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr21-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Creutzfeldt</surname><given-names>C.</given-names></name>
<name><surname>Weinstein</surname><given-names>J.</given-names></name>
<name><surname>Longstreth</surname><given-names>W.</given-names></name>
<name><surname>Becker</surname><given-names>K.</given-names></name>
<name><surname>McPharlin</surname><given-names>T.</given-names></name>
<name><surname>Tirschwell</surname><given-names>D.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage</article-title>. <source>J Stroke Cerebrovasc Dis</source> <volume>18</volume>: <fpage>221</fpage>–<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr22-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cucchiara</surname><given-names>B.</given-names></name>
<name><surname>Messe</surname><given-names>S.</given-names></name>
<name><surname>Sansing</surname><given-names>L.</given-names></name>
<name><surname>Kasner</surname><given-names>S.</given-names></name>
<name><surname>Lyden</surname><given-names>P.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Hematoma growth in oral anticoagulant related intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>39</volume>: <fpage>2993</fpage>–<lpage>2996</lpage>.</citation>
</ref>
<ref id="bibr23-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>S.</given-names></name>
<name><surname>Broderick</surname><given-names>J.</given-names></name>
<name><surname>Hennerici</surname><given-names>M.</given-names></name>
<name><surname>Brun</surname><given-names>N.</given-names></name>
<name><surname>Diringer</surname><given-names>M.</given-names></name>
<name><surname>Mayer</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage</article-title>. <source>Neurology</source> <volume>66</volume>: <fpage>1175</fpage>–<lpage>1181</lpage>.</citation>
</ref>
<ref id="bibr24-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dickneite</surname><given-names>G.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Prothrombin complex concentrate versus recombinant factor viia for reversal of coumarin anticoagulation</article-title>. <source>Thromb Res</source> <volume>119</volume>: <fpage>643</fpage>–<lpage>651</lpage>.</citation>
</ref>
<ref id="bibr25-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dowlatshahi</surname><given-names>D.</given-names></name>
<name><surname>Demchuk</surname><given-names>A.</given-names></name>
<name><surname>Flaherty</surname><given-names>M.</given-names></name>
<name><surname>Ali</surname><given-names>M.</given-names></name>
<name><surname>Lyden</surname><given-names>P.</given-names></name>
<name><surname>Smith</surname><given-names>E.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Defining hematoma expansion in intracerebral hemorrhge – relationship with patient outcomes</article-title>. <source>Neurology</source> <volume>76</volume>: <fpage>1238</fpage>–<lpage>1244</lpage>.</citation>
</ref>
<ref id="bibr26-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ducret</surname><given-names>A.</given-names></name>
<name><surname>Hickman</surname><given-names>Z.</given-names></name>
<name><surname>Zacharia</surname><given-names>B.</given-names></name>
<name><surname>Gorobelny</surname><given-names>B.</given-names></name>
<name><surname>DeRosa</surname><given-names>P.</given-names></name>
<name><surname>Landes</surname><given-names>E.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage</article-title>. <source>Neurol Res</source> <volume>32</volume>: <fpage>706</fpage>–<lpage>710</lpage>.</citation>
</ref>
<ref id="bibr27-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eckman</surname><given-names>M.</given-names></name>
<name><surname>Rosand</surname><given-names>J.</given-names></name>
<name><surname>Knudsen</surname><given-names>K.</given-names></name>
<name><surname>Singer</surname><given-names>D.</given-names></name>
<name><surname>Greenberg</surname><given-names>S.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Can patients be anticoagulated after intracerebral hemorrhage - a decision analysis</article-title>. <source>Stroke</source> <volume>34</volume>: <fpage>1710</fpage>–<lpage>1716</lpage>.</citation>
</ref>
<ref id="bibr28-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fan</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Lam</surname><given-names>W.</given-names></name>
<name><surname>Mok</surname><given-names>V.</given-names></name>
<name><surname>Wong</surname><given-names>K.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke</article-title>. <source>Stroke</source> <volume>34</volume>: <fpage>2459</fpage>–<lpage>2462</lpage>.</citation>
</ref>
<ref id="bibr29-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fiore</surname><given-names>L.</given-names></name>
<name><surname>Scola</surname><given-names>M.</given-names></name>
<name><surname>Cantillon</surname><given-names>C.</given-names></name>
<name><surname>Brophy</surname><given-names>M.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Anaphylactoid reactions to vitamin K</article-title>. <source>J Thromb Thrombolysis</source> <volume>11</volume>: <fpage>175</fpage>–<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr30-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flibotte</surname><given-names>J.</given-names></name>
<name><surname>Hagan</surname><given-names>N.</given-names></name>
<name><surname>O’Donnell</surname><given-names>J.</given-names></name>
<name><surname>Greenberg</surname><given-names>S.</given-names></name>
<name><surname>Rosand</surname><given-names>J.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Warfarin, Hematoma Expansion, and Outcome of Intracerebral Hemorrhage</article-title>. <source>Neurology</source> <volume>63</volume>: <fpage>1059</fpage>–<lpage>1064</lpage>.</citation>
</ref>
<ref id="bibr31-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Foerch</surname><given-names>C.</given-names></name>
<name><surname>Sitzer</surname><given-names>M.</given-names></name>
<name><surname>Steinmetz</surname><given-names>H.</given-names></name>
<name><surname>Neumann-Haefelin</surname><given-names>T.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>37</volume>: <fpage>2165</fpage>–<lpage>2167</lpage>.</citation>
</ref>
<ref id="bibr32-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gebel</surname><given-names>J.</given-names></name>
<name><surname>Jauch</surname><given-names>E.</given-names></name>
<name><surname>Brott</surname><given-names>T.</given-names></name>
<name><surname>Khoury</surname><given-names>J.</given-names></name>
<name><surname>Sauerbeck</surname><given-names>L.</given-names></name>
<name><surname>Salisbury</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2002</year>) <article-title>Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>33</volume>: <fpage>2636</fpage>–<lpage>2641</lpage>.</citation>
</ref>
<ref id="bibr33-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gebel</surname><given-names>J.</given-names></name>
<name><surname>Sila</surname><given-names>C.</given-names></name>
<name><surname>Sloan</surname><given-names>M.</given-names></name>
<name><surname>Granger</surname><given-names>C.</given-names></name>
<name><surname>Mahaffy</surname><given-names>K.</given-names></name>
<name><surname>Weisenberger</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>1998</year>) <article-title>Thrombolysis related intracranial hemorrhage</article-title>. <source>Stroke</source> <volume>29</volume>: <fpage>563</fpage>–<lpage>569</lpage>.</citation>
</ref>
<ref id="bibr34-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Go</surname><given-names>A.</given-names></name>
<name><surname>Hylek</surname><given-names>E.</given-names></name>
<name><surname>Phillips</surname><given-names>K.</given-names></name>
<name><surname>Chang</surname><given-names>Y.</given-names></name>
<name><surname>Henault</surname><given-names>L.</given-names></name>
<name><surname>Selby</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2001</year>) <article-title>Prevalence of diagnosed atrial fibrillation in adults</article-title>. <source>JAMA</source> <volume>285</volume>: <fpage>2370</fpage>–<lpage>2375</lpage>.</citation>
</ref>
<ref id="bibr35-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldstein</surname><given-names>J.</given-names></name>
<name><surname>Fazen</surname><given-names>L.</given-names></name>
<name><surname>Snider</surname><given-names>R.</given-names></name>
<name><surname>Schwab</surname><given-names>K.</given-names></name>
<name><surname>Greenberg</surname><given-names>S.</given-names></name>
<name><surname>Smith</surname><given-names>E.</given-names></name>
<etal/>
</person-group> (<year>2007</year>) <article-title>Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage</article-title>. <source>Neurology</source> <volume>68</volume>: <fpage>889</fpage>–<lpage>894</lpage>.</citation>
</ref>
<ref id="bibr36-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hallevi</surname><given-names>H.</given-names></name>
<name><surname>Albright</surname><given-names>K.</given-names></name>
<name><surname>Aronowski</surname><given-names>J.</given-names></name>
<name><surname>Barreto</surname><given-names>A.</given-names></name>
<name><surname>Schild</surname><given-names>S.</given-names></name>
<name><surname>Khaja</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Intraventricular hemorrhage – anatomic relationships and clinical implications</article-title>. <source>Neurology</source> <volume>70</volume>: <fpage>848</fpage>–<lpage>852</lpage>.</citation>
</ref>
<ref id="bibr37-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hart</surname><given-names>R.</given-names></name>
<name><surname>Boop</surname><given-names>B.</given-names></name>
<name><surname>Anderson</surname><given-names>D.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Oral anticoagulants and intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>26</volume>: <fpage>1471</fpage>–<lpage>1477</lpage>.</citation>
</ref>
<ref id="bibr38-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hemphill</surname><given-names>J.</given-names></name>
<name><surname>Bonovich</surname><given-names>D.</given-names></name>
<name><surname>Besmertis</surname><given-names>L.</given-names></name>
<name><surname>Manley</surname><given-names>G.</given-names></name>
<name><surname>Johnston</surname><given-names>C.</given-names></name>
</person-group> (<year>2001</year>) <article-title>The ICH score – a simple and reliable grading scale for intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>32</volume>: <fpage>891</fpage>–<lpage>897</lpage>.</citation>
</ref>
<ref id="bibr39-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsh</surname><given-names>J.</given-names></name>
<name><surname>Raschke</surname><given-names>R.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Heparin and low molecular heparin – the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy</article-title>. <source>Chest</source> <volume>126</volume>(<supplement>3 Suppl</supplement>): <fpage>188s</fpage>–<lpage>203s</lpage>.</citation>
</ref>
<ref id="bibr40-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoff</surname><given-names>J.</given-names></name>
<name><surname>Xi</surname><given-names>G.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Brain edema from intracerebral hemorrhage</article-title>. <source>Acta Neurochir</source> <volume>86</volume>(<supplement>Suppl</supplement>): <fpage>11</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr41-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holland</surname><given-names>L.</given-names></name>
<name><surname>Brooks</surname><given-names>J.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Toward rational fresh frozen plasma transfusion</article-title>. <source>Am J Clin Pathol</source> <volume>126</volume>: <fpage>133</fpage>–<lpage>139</lpage>.</citation>
</ref>
<ref id="bibr42-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huttner</surname><given-names>H.</given-names></name>
<name><surname>Schellinger</surname><given-names>P.</given-names></name>
<name><surname>Hartmann</surname><given-names>M.</given-names></name>
<name><surname>Kohrmann</surname><given-names>M.</given-names></name>
<name><surname>Juettler</surname><given-names>E.</given-names></name>
<name><surname>Winker</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2006a</year>) <article-title>Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy</article-title>. <source>Stroke</source> <volume>37</volume>: <fpage>1465</fpage>–<lpage>1470</lpage>.</citation>
</ref>
<ref id="bibr43-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huttner</surname><given-names>H.</given-names></name>
<name><surname>Steiner</surname><given-names>T.</given-names></name>
<name><surname>Hartmann</surname><given-names>M.</given-names></name>
<name><surname>Kohrmann</surname><given-names>M.</given-names></name>
<name><surname>Juettler</surname><given-names>E.</given-names></name>
<name><surname>Mueller</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2006b</year>) <article-title>Comparison of ABC/2 estimation technique to computer assisted planimetric analysis in warfarin related intracerebral parenchymal hemorrhage</article-title>. <source>Stroke</source> <volume>37</volume>: <fpage>404</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr44-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ichikawa</surname><given-names>K.</given-names></name>
<name><surname>Yanagihara</surname><given-names>C.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Sedimentation level in acute intracerebral hematoma in a patient receiving anticoagulation therapy – an autopsy study</article-title>. <source>Neuroradiology</source> <volume>40</volume>: <fpage>380</fpage>–<lpage>382</lpage>.</citation>
</ref>
<ref id="bibr45-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ishibashi</surname><given-names>A.</given-names></name>
<name><surname>Yokokura</surname><given-names>Y.</given-names></name>
<name><surname>Adachi</surname><given-names>H.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Is antiplatelet therapy for the prevention of ischemic stroke associated with the prognosis of intracerebral hemorrhage?</article-title>. <source>Kurume Med J</source> <volume>55</volume>: <fpage>71</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr46-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jauch</surname><given-names>E.</given-names></name>
<name><surname>Lindsell</surname><given-names>C.</given-names></name>
<name><surname>Adeoye</surname><given-names>O.</given-names></name>
<name><surname>Khoury</surname><given-names>J.</given-names></name>
<name><surname>Barsan</surname><given-names>W.</given-names></name>
<name><surname>Broderick</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Lack of evidence for an association between hemodynamic variables and hematoma growth in spontaneous intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>37</volume>: <fpage>2061</fpage>–<lpage>2065</lpage>.</citation>
</ref>
<ref id="bibr47-1756285611422267">
<citation citation-type="book">
<collab>Johnson &amp; Johnson</collab> (<year>2009</year>) <article-title>Rivoroxaban</article-title>. <publisher-loc>New Brunswick, NJ; USA</publisher-loc>.</citation>
</ref>
<ref id="bibr48-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kalita</surname><given-names>J.</given-names></name>
<name><surname>Misra</surname><given-names>U.</given-names></name>
<name><surname>Ranjan</surname><given-names>P.</given-names></name>
<name><surname>Pradhan</surname><given-names>P.</given-names></name>
<name><surname>Das</surname><given-names>B.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Effect of mannitol on regional CBF in patients with intracerebral hemorrhage</article-title>. <source>J Neurol Sci</source> <volume>224</volume>: <fpage>19</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr49-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Kopp</surname><given-names>S.</given-names></name>
<name><surname>Dugan</surname><given-names>L.</given-names></name>
<name><surname>Diringer</surname><given-names>M.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Perihematomal mitochondrial dysfunction after intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>37</volume>: <fpage>2457</fpage>–<lpage>2462</lpage>.</citation>
</ref>
<ref id="bibr50-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kollmar</surname><given-names>R.</given-names></name>
<name><surname>Schabitz</surname><given-names>W.</given-names></name>
<name><surname>Heiland</surname><given-names>S.</given-names></name>
<name><surname>Georgiadis</surname><given-names>D.</given-names></name>
<name><surname>Schellinger</surname><given-names>P.</given-names></name>
<name><surname>Bardutzky</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2002</year>) <article-title>Neuroprotective effect of delayed moderate hypothermia after focal cerebral ischemia – an MRI study</article-title>. <source>Stroke</source> <volume>33</volume>: <fpage>1899</fpage>–<lpage>1904</lpage>.</citation>
</ref>
<ref id="bibr51-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kollmar</surname><given-names>R.</given-names></name>
<name><surname>Staykov</surname><given-names>D.</given-names></name>
<name><surname>Dorfler</surname><given-names>A.</given-names></name>
<name><surname>Schellinger</surname><given-names>P.</given-names></name>
<name><surname>Schwab</surname><given-names>S.</given-names></name>
<name><surname>Bardutzky</surname><given-names>J.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Hypothermia reduces perihemorrhagic edema after intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>41</volume>: <fpage>1684</fpage>–<lpage>1689</lpage>.</citation>
</ref>
<ref id="bibr52-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kothari</surname><given-names>R.</given-names></name>
<name><surname>Brott</surname><given-names>T.</given-names></name>
<name><surname>Broderick</surname><given-names>J.</given-names></name>
<name><surname>Barsan</surname><given-names>W.</given-names></name>
<name><surname>Sauerbeck</surname><given-names>L.</given-names></name>
<name><surname>Zuccarello</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>1996</year>) <article-title>The ABCs of measuring intracerebral hemorrhage volumes</article-title>. <source>Stroke</source> <volume>27</volume>: <fpage>1304</fpage>–<lpage>1305</lpage>.</citation>
</ref>
<ref id="bibr53-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lacut</surname><given-names>K.</given-names></name>
<name><surname>Le Gal</surname><given-names>G.</given-names></name>
<name><surname>Seizeur</surname><given-names>R.</given-names></name>
<name><surname>Prat</surname><given-names>G.</given-names></name>
<name><surname>Mottier</surname><given-names>D.</given-names></name>
<name><surname>Oger</surname><given-names>E.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Antiplatelet drug use preceding the onset of intracerebral hemorrhage is associated with increased mortality</article-title>. <source>Fundam Clin Pharmacol</source> <volume>21</volume>: <fpage>327</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr54-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lauer</surname><given-names>A.</given-names></name>
<name><surname>Schlunk</surname><given-names>F.</given-names></name>
<name><surname>Van Cott</surname><given-names>E.</given-names></name>
<name><surname>Steinmetz</surname><given-names>H.</given-names></name>
<name><surname>Lo</surname><given-names>E.</given-names></name>
<name><surname>Foerch</surname><given-names>C.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Antiplatelt pretreatment does not increase hematoma volume in experimental intracerebral hemorrhage</article-title>. <source>J Cereb Blood Flow Metab</source> <volume>31</volume>: <fpage>1736</fpage>–<lpage>1742</lpage>.</citation>
</ref>
<ref id="bibr55-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Manno</surname><given-names>E.</given-names></name>
<name><surname>Layton</surname><given-names>K.</given-names></name>
<name><surname>Wijdicks</surname><given-names>E.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Progression of warfarin associated intracerebral hemorrhage after INR normalization with FFP</article-title>. <source>Neurology</source> <volume>67</volume>: <fpage>1272</fpage>–<lpage>1274</lpage>.</citation>
</ref>
<ref id="bibr56-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leissinger</surname><given-names>C.</given-names></name>
<name><surname>Blatt</surname><given-names>P.</given-names></name>
<name><surname>Hoots</surname><given-names>W.</given-names></name>
<name><surname>Ewenstein</surname><given-names>B.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Role of prothrombin complex concentrates in reversing warfarin anticoagulation – a review of the literature</article-title>. <source>Am J Hematol</source> <volume>83</volume>: <fpage>137</fpage>–<lpage>143</lpage>.</citation>
</ref>
<ref id="bibr57-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levy</surname><given-names>J.</given-names></name>
<name><surname>Key</surname><given-names>N.</given-names></name>
<name><surname>Azran</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Novel oral anticoagulants – implications in the perioperative setting</article-title>. <source>Anesthesiology</source> <volume>113</volume>: <fpage>726</fpage>–<lpage>745</lpage>.</citation>
</ref>
<ref id="bibr58-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>MacLellan</surname><given-names>C.</given-names></name>
<name><surname>Davies</surname><given-names>L.</given-names></name>
<name><surname>Fingas</surname><given-names>M.</given-names></name>
<name><surname>Colbourne</surname><given-names>F.</given-names></name>
</person-group> (<year>2006</year>) <article-title>The influence of hypothermia on outcome after intracerebral hemorrhage in rats</article-title>. <source>Stroke</source> <volume>37</volume>: <fpage>1266</fpage>–<lpage>1270</lpage>.</citation>
</ref>
<ref id="bibr59-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>MacLellan</surname><given-names>C.</given-names></name>
<name><surname>Girgis</surname><given-names>J.</given-names></name>
<name><surname>Colbourne</surname><given-names>F.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Delayed onset of prolonged hypothermia improves outcome after intracerebral hemorrhage in rats</article-title>. <source>J Cereb Blood Flow Metab</source> <volume>24</volume>: <fpage>432</fpage>–<lpage>440</lpage>.</citation>
</ref>
<ref id="bibr60-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Makris</surname><given-names>M.</given-names></name>
<name><surname>Greaves</surname><given-names>M.</given-names></name>
<name><surname>Phillips</surname><given-names>W.</given-names></name>
<name><surname>Kitchen</surname><given-names>S.</given-names></name>
<name><surname>Rosendaal</surname><given-names>F.</given-names></name>
<name><surname>Preston</surname><given-names>E.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Emergency oral anticoagulant reversal – the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy</article-title>. <source>Thromb Haemost</source> <volume>77</volume>: <fpage>477</fpage>–<lpage>480</lpage>.</citation>
</ref>
<ref id="bibr61-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mayer</surname><given-names>S.</given-names></name>
<name><surname>Brun</surname><given-names>N.</given-names></name>
<name><surname>Begtrup</surname><given-names>K.</given-names></name>
<name><surname>Broderick</surname><given-names>J.</given-names></name>
<name><surname>Davis</surname><given-names>S.</given-names></name>
<name><surname>Diringer</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2005</year>) <article-title>Recombinant activated factor VII for acute uintracerebral hemorrhage</article-title>. <source>N Eng J Med</source> <volume>352</volume>: <fpage>777</fpage>–<lpage>785</lpage>.</citation>
</ref>
<ref id="bibr62-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mayer</surname><given-names>S.</given-names></name>
<name><surname>Brun</surname><given-names>N.</given-names></name>
<name><surname>Begtrup</surname><given-names>K.</given-names></name>
<name><surname>Broderick</surname><given-names>J.</given-names></name>
<name><surname>Davis</surname><given-names>S.</given-names></name>
<name><surname>Diringer</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage</article-title>. <source>N Eng J Med</source> <volume>358</volume>: <fpage>2127</fpage>–<lpage>2137</lpage>.</citation>
</ref>
<ref id="bibr63-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mayer</surname><given-names>S.</given-names></name>
<name><surname>Davis</surname><given-names>S.</given-names></name>
<name><surname>Skolnick</surname><given-names>B.</given-names></name>
<name><surname>Brun</surname><given-names>N.</given-names></name>
<name><surname>Begrrup</surname><given-names>K.</given-names></name>
<name><surname>Broderick</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2009</year>) <article-title>Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII?</article-title>. <source>Stroke</source> <volume>40</volume>: <fpage>833</fpage>–<lpage>840</lpage>.</citation>
</ref>
<ref id="bibr64-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mendelow</surname><given-names>A.</given-names></name>
<name><surname>Gregson</surname><given-names>B.</given-names></name>
<name><surname>Fernandes</surname><given-names>H.</given-names></name>
<name><surname>Murray</surname><given-names>G.</given-names></name>
<name><surname>Teasdale</surname><given-names>G.</given-names></name>
<name><surname>Hope</surname><given-names>D.</given-names></name>
<etal/>
</person-group> (<year>2005</year>) <article-title>Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral hematomas in the International Surgical Trial in Intracerebral Hemorrhage (STICH) – a randomized trial</article-title>. <source>Lancet</source> <volume>365</volume>: <fpage>387</fpage>–<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr65-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Misra</surname><given-names>U.</given-names></name>
<name><surname>Kalita</surname><given-names>J.</given-names></name>
<name><surname>Ranjan</surname><given-names>P.</given-names></name>
<name><surname>Nandal</surname><given-names>S.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Mannitol in intracerebral hemorrhage – a randomized controlled study</article-title>. <source>J Neurol Sci</source> <volume>234</volume>: <fpage>41</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr66-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morgensetern</surname><given-names>L.</given-names></name>
<name><surname>Hemphill</surname><given-names>J.</given-names></name>
<name><surname>Anderson</surname><given-names>C.</given-names></name>
<name><surname>Becker</surname><given-names>K.</given-names></name>
<name><surname>Broderick</surname><given-names>J.</given-names></name>
<name><surname>Connolly</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Guidelines for the management of spontaneous intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>41</volume>: <fpage>2108</fpage>–<lpage>2129</lpage>.</citation>
</ref>
<ref id="bibr67-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moussouttas</surname><given-names>M.</given-names></name>
<name><surname>Malhotra</surname><given-names>R.</given-names></name>
<name><surname>Fernandez</surname><given-names>L.</given-names></name>
<name><surname>Maltenfort</surname><given-names>M.</given-names></name>
<name><surname>Holowecki</surname><given-names>M.</given-names></name>
<name><surname>Delgado</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Role of antiplatelet agents in hematoma expansion during the acute period of intracerebral hemorrhage</article-title>. <source>Neurocrit Care</source> <volume>12</volume>: <fpage>24</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr68-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moussouttas</surname><given-names>M.</given-names></name>
<name><surname>Malhotra</surname><given-names>R.</given-names></name>
<name><surname>Fernandez</surname><given-names>L.</given-names></name>
<name><surname>Maltnefort</surname><given-names>M.</given-names></name>
<name><surname>Holowecki</surname><given-names>M.</given-names></name>
<name><surname>Delgado</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2011</year>) <article-title>Impact of intraventricular hemorrhage upon intracerebral hematoma expansion</article-title>. <source>Neurocrit Care</source> <volume>14</volume>: <fpage>50</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr69-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Naidech</surname><given-names>A.</given-names></name>
<name><surname>Bassin</surname><given-names>S.</given-names></name>
<name><surname>Bernstein</surname><given-names>R.</given-names></name>
<name><surname>Batjer</surname><given-names>H.</given-names></name>
<name><surname>Alberts</surname><given-names>M.</given-names></name>
<name><surname>Lindholm</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2009a</year>) <article-title>Reduced platelet activity is more common than reported antiplatelet medication use in patients with intracerebral hemorrhage</article-title>. <source>Neurocrit Care</source> <volume>11</volume>: <fpage>307</fpage>–<lpage>310</lpage>.</citation>
</ref>
<ref id="bibr70-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Naidech</surname><given-names>A.</given-names></name>
<name><surname>Bernstein</surname><given-names>R.</given-names></name>
<name><surname>Levasseur</surname><given-names>K.</given-names></name>
<name><surname>Bassin</surname><given-names>S.</given-names></name>
<name><surname>Bendok</surname><given-names>B.</given-names></name>
<name><surname>Batjer</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2009b</year>) <article-title>Platelet activity and outcome after intracerebral hemorrhage</article-title>. <source>Ann Neurol</source> <volume>65</volume>: <fpage>352</fpage>–<lpage>356</lpage>.</citation>
</ref>
<ref id="bibr71-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Naidech</surname><given-names>A.M.</given-names></name>
<name><surname>Jovanovic</surname><given-names>B.</given-names></name>
<name><surname>Liebling</surname><given-names>S.</given-names></name>
<name><surname>Garg</surname><given-names>R.K.</given-names></name>
<name><surname>Bassin</surname><given-names>S.L.</given-names></name>
<name><surname>Bendok</surname><given-names>B.R.</given-names></name>
<etal/>
</person-group> (<year>2009c</year>) <article-title>Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>40</volume>: <fpage>2398</fpage>–<lpage>2401</lpage>.</citation>
</ref>
<ref id="bibr72-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Donnell</surname><given-names>H.</given-names></name>
<name><surname>Rosand</surname><given-names>J.</given-names></name>
<name><surname>Knudsen</surname><given-names>K.</given-names></name>
<name><surname>Furle</surname><given-names>K.</given-names></name>
<name><surname>Segal</surname><given-names>A.</given-names></name>
<name><surname>Chiu</surname><given-names>R.</given-names></name>
<etal/>
</person-group> (<year>2000</year>) <article-title>Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage</article-title>. <source>N Eng J Med</source> <volume>342</volume>: <fpage>240</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr73-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olivot</surname><given-names>J.</given-names></name>
<name><surname>Miynash</surname><given-names>M.</given-names></name>
<name><surname>Kleinman</surname><given-names>J.</given-names></name>
<name><surname>Straka</surname><given-names>M.</given-names></name>
<name><surname>Venkatasubramanian</surname><given-names>C.</given-names></name>
<name><surname>Bammer</surname><given-names>R.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>MRI profile of the perihematomal region in acute intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>41</volume>: <fpage>2681</fpage>–<lpage>2683</lpage>.</citation>
</ref>
<ref id="bibr74-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pantazis</surname><given-names>G.</given-names></name>
<name><surname>Tsitsopoulos</surname><given-names>P.</given-names></name>
<name><surname>Mihas</surname><given-names>C.</given-names></name>
<name><surname>Katsiva</surname><given-names>V.</given-names></name>
<name><surname>Stavrianos</surname><given-names>V.</given-names></name>
<name><surname>Zymaris</surname><given-names>S.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Early surgical treatment versus conservative management for spontaneous supratentorial intracerebral hematomas – a prospective randomized study</article-title>. <source>Surg Neurol</source> <volume>66</volume>: <fpage>492</fpage>–<lpage>501</lpage>.</citation>
</ref>
<ref id="bibr75-1756285611422267">
<citation citation-type="book">
<collab>Pfizer</collab> (<year>2007</year>) <article-title>Dalteparin sodium</article-title>. <publisher-loc>New York, NY; USA</publisher-loc>.</citation>
</ref>
<ref id="bibr76-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polderman</surname><given-names>K.</given-names></name>
<name><surname>Herold</surname><given-names>I.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Therapeutic hypothermia and controlled normothermia in the intensive care unit – practical considerations, side effects and cooling methods</article-title>. <source>Crit Care Med</source> <volume>37</volume>: <fpage>1101</fpage>–<lpage>1120</lpage>.</citation>
</ref>
<ref id="bibr77-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poungvarin</surname><given-names>N.</given-names></name>
<name><surname>Bhoopat</surname><given-names>W.</given-names></name>
<name><surname>Viriyavejakul</surname><given-names>A.</given-names></name>
<name><surname>Rodprasert</surname><given-names>P.</given-names></name>
<name><surname>Buranasiri</surname><given-names>P.</given-names></name>
<name><surname>Sukondhabhant</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>1987</year>) <article-title>Effects of dexamethasone in primary supratentorial intracerebral hemorrhage</article-title>. <source>N Eng J Med</source> <volume>316</volume>: <fpage>1229</fpage>–<lpage>1233</lpage>.</citation>
</ref>
<ref id="bibr78-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qureshi</surname><given-names>A.</given-names></name>
<name><surname>Mendelow</surname><given-names>A.</given-names></name>
<name><surname>Hanley</surname><given-names>D.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Intracerebral hemorrhage</article-title>. <source>Lancet</source> <volume>373</volume>: <fpage>1632</fpage>–<lpage>1644</lpage>.</citation>
</ref>
<ref id="bibr79-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qureshi</surname><given-names>A.</given-names></name>
<name><surname>Palesch</surname><given-names>Y.</given-names></name>
<name><surname>Martin</surname><given-names>R.</given-names></name>
<name><surname>Novitzke</surname><given-names>J.</given-names></name>
<name><surname>Cruz</surname><given-names>S.</given-names></name>
<name><surname>Ehtisham</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage</article-title>. <source>Arch Neurol</source> <volume>67</volume>: <fpage>570</fpage>–<lpage>576</lpage>.</citation>
</ref>
<ref id="bibr80-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raj</surname><given-names>G.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>McKinney</surname><given-names>W.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione</article-title>. <source>Arch Intern Med</source> <volume>159</volume>: <fpage>2721</fpage>–<lpage>2724</lpage>.</citation>
</ref>
<ref id="bibr81-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Refaai</surname><given-names>M.</given-names></name>
<name><surname>Phipps</surname><given-names>R.</given-names></name>
<name><surname>Spinelli</surname><given-names>S.</given-names></name>
<name><surname>Blumberg</surname><given-names>N.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Platelet transfusions – impact on hemostasis, thrombosis, inflammation, and clinical outcomes</article-title>. <source>Thromb Res</source> <volume>127</volume>: <fpage>287</fpage>–<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr82-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>H.</given-names></name>
<name><surname>Monroe</surname><given-names>D.</given-names></name>
<name><surname>White</surname><given-names>G.</given-names></name>
</person-group> (<year>2004</year>) <article-title>The use of recombinant factor VIIa in the treatment of bleeding disorders</article-title>. <source>Blood</source> <volume>104</volume>: <fpage>3858</fpage>–<lpage>3864</lpage>.</citation>
</ref>
<ref id="bibr83-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roquer</surname><given-names>J.</given-names></name>
<name><surname>Rodriguez</surname><given-names>A.</given-names></name>
<name><surname>Gomis</surname><given-names>M.</given-names></name>
<name><surname>Ois</surname><given-names>A.</given-names></name>
<name><surname>Puente</surname><given-names>V.</given-names></name>
<name><surname>Munteis</surname><given-names>E.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage</article-title>. <source>J Neurol</source> <volume>252</volume>: <fpage>412</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr84-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sacco</surname><given-names>R.</given-names></name>
<name><surname>Adams</surname><given-names>R.</given-names></name>
<name><surname>Albers</surname><given-names>G.</given-names></name>
<name><surname>Alberts</surname><given-names>M.</given-names></name>
<name><surname>Benavente</surname><given-names>O.</given-names></name>
<name><surname>Furie</surname><given-names>K.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack</article-title>. <source>Stroke</source> <volume>37</volume>: <fpage>577</fpage>–<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr85-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saloheimo</surname><given-names>P.</given-names></name>
<name><surname>Ahonen</surname><given-names>M.</given-names></name>
<name><surname>Juvela</surname><given-names>S.</given-names></name>
<name><surname>Pyhtinen</surname><given-names>J.</given-names></name>
<name><surname>Savolainen</surname><given-names>E.</given-names></name>
<name><surname>Hillbom</surname><given-names>M.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Regular aspirin use preceding the onset of primary inracerebral hemorrhage is an independent predictor for death</article-title>. <source>Stroke</source> <volume>37</volume>: <fpage>129</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr86-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sansing</surname><given-names>L.</given-names></name>
<name><surname>Kaznatcheeva</surname><given-names>E.</given-names></name>
<name><surname>Perkins</surname><given-names>C.</given-names></name>
<name><surname>Komaroff</surname><given-names>E.</given-names></name>
<name><surname>Gutman</surname><given-names>F.</given-names></name>
<name><surname>Newman</surname><given-names>G.</given-names></name>
</person-group> (<year>2003</year>) <article-title>edema after intracerebral hemorrhage – correlations with coagulation parameters and treatment</article-title>. <source>J Neurosurg</source> <volume>98</volume>: <fpage>985</fpage>–<lpage>992</lpage>.</citation>
</ref>
<ref id="bibr87-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sansing</surname><given-names>L.</given-names></name>
<name><surname>Messe</surname><given-names>S.</given-names></name>
<name><surname>Cucchiara</surname><given-names>B.</given-names></name>
<name><surname>Cohen</surname><given-names>S.</given-names></name>
<name><surname>Lyden</surname><given-names>P.</given-names></name>
<name><surname>Kasner</surname><given-names>S.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH</article-title>. <source>Neurology</source> <volume>72</volume>: <fpage>1397</fpage>–<lpage>1402</lpage>.</citation>
</ref>
<ref id="bibr88-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schulman</surname><given-names>S.</given-names></name>
<name><surname>Kearon</surname><given-names>C.</given-names></name>
<name><surname>Kakkar</surname><given-names>A.</given-names></name>
<name><surname>Mismetti</surname><given-names>P.</given-names></name>
<name><surname>Schellong</surname><given-names>S.</given-names></name>
<name><surname>Eriksson</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2009</year>) <article-title>Dabigatran versus warfarin in the treatment of acute venous thromboembolism</article-title>. <source>N Eng J Med</source> <volume>361</volume>: <fpage>2342</fpage>–<lpage>2352</lpage>.</citation>
</ref>
<ref id="bibr89-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schwab</surname><given-names>S.</given-names></name>
<name><surname>Georgiadis</surname><given-names>D.</given-names></name>
<name><surname>Berrouschot</surname><given-names>J.</given-names></name>
<name><surname>Schellinger</surname><given-names>P.</given-names></name>
<name><surname>Graffagnino</surname><given-names>C.</given-names></name>
<name><surname>Mayer</surname><given-names>S.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Feasibility and safety of moderate hypothermia after massive hemispheric infarction</article-title>. <source>Stroke</source> <volume>32</volume>: <fpage>2033</fpage>–<lpage>2035</lpage>.</citation>
</ref>
<ref id="bibr90-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siddique</surname><given-names>M.</given-names></name>
<name><surname>Fernandes</surname><given-names>H.</given-names></name>
<name><surname>Wooldridge</surname><given-names>T.</given-names></name>
<name><surname>Fenwick</surname><given-names>J.</given-names></name>
<name><surname>Slomka</surname><given-names>P.</given-names></name>
<name><surname>Mendelow</surname><given-names>A.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Reversible ischemia around intracerebral hemorrhage – a single photon emission computerized tomography study</article-title>. <source>J Neurosurg</source> <volume>96</volume>: <fpage>736</fpage>–<lpage>741</lpage>.</citation>
</ref>
<ref id="bibr91-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silva</surname><given-names>Y.</given-names></name>
<name><surname>Leira</surname><given-names>R.</given-names></name>
<name><surname>Tejada</surname><given-names>J.</given-names></name>
<name><surname>Lainez</surname><given-names>J.</given-names></name>
<name><surname>Castillo</surname><given-names>J.</given-names></name>
<name><surname>Davalos</surname><given-names>A.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>36</volume>: <fpage>86</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr92-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skolnick</surname><given-names>B.</given-names></name>
<name><surname>Mathews</surname><given-names>D.</given-names></name>
<name><surname>Khutoryansky</surname><given-names>N.</given-names></name>
<name><surname>Pusateri</surname><given-names>A.</given-names></name>
<name><surname>Carr</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects</article-title>. <source>Blood</source> <volume>116</volume>: <fpage>693</fpage>–<lpage>701</lpage>.</citation>
</ref>
<ref id="bibr93-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sorimachi</surname><given-names>T.</given-names></name>
<name><surname>Fujii</surname><given-names>Y.</given-names></name>
<name><surname>Morita</surname><given-names>K.</given-names></name>
<name><surname>Tanaka</surname><given-names>R.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Predictors of hematoma enlargement in patients with intracerebral hemorrhage treated with rapid administration of antifibrinolytic agents and strict blood pressure control</article-title>. <source>J Neurosurg</source> <volume>106</volume>: <fpage>250</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr94-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steiner</surname><given-names>T.</given-names></name>
<name><surname>Diringer</surname><given-names>M.</given-names></name>
<name><surname>Schneider</surname><given-names>D.</given-names></name>
<name><surname>Mayer</surname><given-names>S.</given-names></name>
<name><surname>Begtrup</surname><given-names>K.</given-names></name>
<name><surname>Broderick</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2006a</year>) <article-title>Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage - risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII</article-title>. <source>Neurosurgery</source> <volume>59</volume>: <fpage>767</fpage>–<lpage>774</lpage>.</citation>
</ref>
<ref id="bibr95-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steiner</surname><given-names>T.</given-names></name>
<name><surname>Rosand</surname><given-names>J.</given-names></name>
<name><surname>Diringer</surname><given-names>M.</given-names></name>
</person-group> (<year>2006b</year>) <article-title>Intracerebral hemorrhage associated with oral anticoagulant therapy – current practices and unresolved questions</article-title>. <source>Stroke</source> <volume>37</volume>: <fpage>256</fpage>–<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr96-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stratmann</surname><given-names>G.</given-names></name>
<name><surname>DeSilva</surname><given-names>A.</given-names></name>
<name><surname>Tseng</surname><given-names>E.</given-names></name>
<name><surname>Hambleton</surname><given-names>J.</given-names></name>
<name><surname>Balea</surname><given-names>M.</given-names></name>
<name><surname>Romo</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2004</year>) <article-title>Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin induced thrombocytopenia</article-title>. <source>Anesth Analg</source> <volume>98</volume>: <fpage>1635</fpage>–<lpage>1639</lpage>.</citation>
</ref>
<ref id="bibr97-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sudlow</surname><given-names>C.</given-names></name>
<name><surname>Warlow</surname><given-names>C.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Comparable studies of the incidence of stroke and its pathological types – results from an international collaboration</article-title>. <source>Stroke</source> <volume>28</volume>: <fpage>491</fpage>–<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr98-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tanaka</surname><given-names>R.</given-names></name>
<name><surname>Szlam</surname><given-names>F.</given-names></name>
<name><surname>Dickneite</surname><given-names>G.</given-names></name>
<name><surname>Levy</surname><given-names>J.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin k antagonist induced anticoagulation</article-title>. <source>Thromb Res</source> <volume>122</volume>: <fpage>117</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr99-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tellez</surname><given-names>H.</given-names></name>
<name><surname>Bauer</surname><given-names>R.</given-names></name>
</person-group> (<year>1973</year>) <article-title>Dexamethasone as treatment in cerebrovascular disease – a controlled study in ICH</article-title>. <source>Stroke</source> <volume>4</volume>: <fpage>541</fpage>–<lpage>546</lpage>.</citation>
</ref>
<ref id="bibr100-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toyoda</surname><given-names>K.</given-names></name>
<name><surname>Okada</surname><given-names>Y.</given-names></name>
<name><surname>Minematsu</surname><given-names>K.</given-names></name>
<name><surname>Kamouchi</surname><given-names>M.</given-names></name>
<name><surname>Fujimoto</surname><given-names>S.</given-names></name>
<name><surname>Ibayashi</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2005</year>) <article-title>Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage</article-title>. <source>Neurology</source> <volume>65</volume>: <fpage>1000</fpage>–<lpage>1004</lpage>.</citation>
</ref>
<ref id="bibr101-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toyoda</surname><given-names>K.</given-names></name>
<name><surname>Yasaka</surname><given-names>M.</given-names></name>
<name><surname>Nagata</surname><given-names>K.</given-names></name>
<name><surname>Nagao</surname><given-names>T.</given-names></name>
<name><surname>Gotoh</surname><given-names>J.</given-names></name>
<name><surname>Sakamoto</surname><given-names>T.</given-names></name>
<etal/>
</person-group> (<year>2009</year>) <article-title>Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage</article-title>. <source>Cerebrovasc Dis</source> <volume>27</volume>: <fpage>151</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr102-1756285611422267">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Van Ryn</surname><given-names>J.</given-names></name>
<name><surname>Sieger</surname><given-names>P.</given-names></name>
<name><surname>Kink</surname><given-names>M.</given-names></name>
<name><surname>Gansser</surname><given-names>D.</given-names></name>
<name><surname>Clemens</surname><given-names>A.</given-names></name>
</person-group> (<year>2009</year>) <source>Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro [abstract]</source> <publisher-loc>New Orleans, LA</publisher-loc>: <publisher-name>American Society of Hematology</publisher-name>.</citation>
</ref>
<ref id="bibr103-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Ryn</surname><given-names>J.</given-names></name>
<name><surname>Stangier</surname><given-names>J.</given-names></name>
<name><surname>Haertter</surname><given-names>S.</given-names></name>
<name><surname>Liesenfeld</surname><given-names>K.</given-names></name>
<name><surname>Wienen</surname><given-names>W.</given-names></name>
<name><surname>Feuring</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2010</year>) <article-title>Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity</article-title>. <source>Thromb Haemost</source> <volume>103</volume>: <fpage>1116</fpage>–<lpage>1127</lpage>.</citation>
</ref>
<ref id="bibr104-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vermeer</surname><given-names>S.</given-names></name>
<name><surname>Algra</surname><given-names>A.</given-names></name>
<name><surname>Franke</surname><given-names>C.</given-names></name>
<name><surname>Koudstaal</surname><given-names>P.</given-names></name>
<name><surname>Rinkel</surname><given-names>G.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Long term prognosis after recovery from primary intracerebral hemorrhage</article-title>. <source>Neurology</source> <volume>59</volume>: <fpage>205</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr105-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vernooij</surname><given-names>M.</given-names></name>
<name><surname>van der Lugt</surname><given-names>A.</given-names></name>
<name><surname>Ikram</surname><given-names>M.</given-names></name>
<name><surname>Wielopolski</surname><given-names>P.</given-names></name>
<name><surname>Niessen</surname><given-names>W.</given-names></name>
<name><surname>Hofman</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Prevalence and risk factors of cerebral microbleeds – the Rotterdam Study</article-title>. <source>Neurology</source> <volume>70</volume>: <fpage>1208</fpage>–<lpage>1214</lpage>.</citation>
</ref>
<ref id="bibr106-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Viswanathan</surname><given-names>A.</given-names></name>
<name><surname>Rakich</surname><given-names>S.</given-names></name>
<name><surname>Engel</surname><given-names>C.</given-names></name>
<name><surname>Snider</surname><given-names>R.</given-names></name>
<name><surname>Rosand</surname><given-names>J.</given-names></name>
<name><surname>Greenberg</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Antiplatelet use after intracerebral hemorrhage</article-title>. <source>Neurology</source> <volume>66</volume>: <fpage>206</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr107-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wada</surname><given-names>R.</given-names></name>
<name><surname>Aviv</surname><given-names>R.</given-names></name>
<name><surname>Fox</surname><given-names>A.</given-names></name>
<name><surname>Sahlas</surname><given-names>D.</given-names></name>
<name><surname>Gladstone</surname><given-names>D.</given-names></name>
<name><surname>Tomlinson</surname><given-names>G.</given-names></name>
<etal/>
</person-group> (<year>2007</year>) <article-title>CT angiography spot sign predicts hematoma expansion in acute intracerebral hemorrhage</article-title>. <source>Stroke</source> <volume>38</volume>: <fpage>1257</fpage>–<lpage>1262</lpage>.</citation>
</ref>
<ref id="bibr108-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Watson</surname><given-names>H.</given-names></name>
<name><surname>Baglin</surname><given-names>T.</given-names></name>
<name><surname>Laidlaw</surname><given-names>S.</given-names></name>
<name><surname>Makris</surname><given-names>M.</given-names></name>
<name><surname>Preston</surname><given-names>E.</given-names></name>
</person-group> (<year>2001</year>) <article-title>A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin</article-title>. <source>Br J Haematol</source> <volume>115</volume>: <fpage>145</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr109-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yildiz</surname><given-names>O.</given-names></name>
<name><surname>Arsava</surname><given-names>E.</given-names></name>
<name><surname>Akpinar</surname><given-names>E.</given-names></name>
<name><surname>Topcuoglu</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Previous antiplatelet use is associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage</article-title>. <source>J Stroke Cerebrovasc Dis</source> <volume>15</volume>, <comment>June [epub ahead of print]</comment>.</citation>
</ref>
<ref id="bibr110-1756285611422267">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Kumana</surname><given-names>C.</given-names></name>
<name><surname>Lauder</surname><given-names>I.</given-names></name>
<name><surname>Cheung</surname><given-names>Y.</given-names></name>
<name><surname>Chan</surname><given-names>F.</given-names></name>
<name><surname>Kou</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>1992</year>) <article-title>Treatment of acute cerebral hemorrhage with intravenous glycerol – a double blind placebo controlled randomized trial</article-title>. <source>Stroke</source> <volume>23</volume>: <fpage>967</fpage>–<lpage>971</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>